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ABSTRACT OF THE DISSERTATION 
Evaluating the Structural and Functional Consequences of Traumatic Joint Injury and 
their Relation to NF-κB in a Non-Invasive Model of Post-traumatic Osteoarthritis 
by 
Ian Matthew Berke 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2021 
Professor Lori A. Setton, Chair 
Post-traumatic osteoarthritis (PTOA) is a painful and debilitating disease of the 
synovial joint, characterized by degenerative changes to various joint tissues following 
traumatic joint injury. While several risk factors have been identified in the symptomatic 
progression of PTOA following injury, inflammation and NF-κB mediated changes are 
believed to significantly contribute to symptomatic joint dysfunction and pain. However, 
the temporal presentation of these pro-inflammatory signals following clinically relevant 
injury and their relationship to the development of symptomatic disease have not been 
thoroughly investigated. Therefore, there exists a critical need to better understand how 
these early inflammatory events following injury may contribute to the symptomatic 
progression of PTOA.  
In the first aim of this dissertation, the temporal relationship between NF-κB 
activation and the development of pain-sensitivity related behaviors following joint injury 
was evaluated in a non-invasive murine model of PTOA. Early activation of NF-κB 
following traumatic knee joint injury was associated with several clinically relevant 
changes in animal behavior including the acute presentation of allodynia, hyperalgesia, 
xii 
 
and transient alterations to weight bearing and ambulation/gait. Persistent unilateral 
allodynia was observed up to 4 months following injury. Furthermore, early NF-κB 
activation following injury was correlated with the severity of chronic allodynia and erosive 
changes to articular cartilage. Data from this aim was used to define an early therapeutic 
treatment window to test the efficacy of a locally delivered NF-κB inhibitor, PHA-408, 
following joint injury.  
Given the involvement of the NF-κB pathway in inflammation and in the 
development of symptomatic PTOA, it was hypothesized that acute local pharmacologic 
NF-κB inhibition might slow the progression of symptomatic PTOA following joint injury. 
Findings in this aim highlighted the early chondroprotective effects of local PHA-408 
following mechanical joint injury. Modest improvements in pain-sensitivity related 
outcomes with repeated drug treatment were also observed. Nevertheless, local delivery 
of PHA-408 failed to modify long-term degenerative changes to articular cartilage. 
Engineered drug depots were also developed for the sustained release of PHA-408. 
While these microparticle based depots showed the potential for sustained drug release 
and inhibition of NF-κB in vitro, their use did not improve measured outcomes following 
joint injury. 
While the painful symptoms and debilitating impact of chronic conditions, such as 
PTOA, may be apparent to the patients who suffer from the disease, many aspects of 
sensory excitability which may contribute to pain, particularly in intact tissue, remain 
unclear. Work in the final aim of this dissertation described the development of an ex vivo 
imaging approach to functionally evaluate sensory neuron excitability within intact dorsal 
root ganglion tissues. This method was capable of simultaneously assessing functional 
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signaling dynamics in hundreds of neurons with single-cell resolution and was further able 
to evaluate alterations to neural signaling following pharmacologic modulation and injury.  
Overall, this dissertation serves to improve our understanding of the symptomatic 
progression of PTOA following traumatic joint injury and highlights many of the challenges 
of intra-articular drug delivery in the disease-modifying treatment of PTOA. Furthermore, 
the novel imaging methods developed within this dissertation may help to elucidate the 
structural and functional changes to musculoskeletal and peripheral nervous system 










1.1 Osteoarthritis, a whole-joint disease 
Osteoarthritis (OA) is one of the top three leading causes of disability in the United 
States where it is estimated to affect over 30 million adults1–3. Globally more than 10% of 
adults over the age of 60 suffer from symptomatic OA2,4. In these individuals severe 
mobility limitations negatively impact quality of life and concurrently increase the risk for 
other chronic conditions such as obesity and cardiovascular disease5–8. In addition to the 
direct impacts on quality of life, OA imparts a substantial economic burden on society. 
Within the United States, arthritis-attributed medical expenditures and earnings losses 
are estimated at over $300 billion annually9. These costs account for nearly 3% of the 
United States gross domestic product9–11. Similar disease related economic impacts have 
been reported globally12. While decades of research have identified several risk factors 
associated with an increased incidence of OA including age, gender, activity level, prior 
injury, obesity, and genetics, there remain no effective disease-modifying OA treatments 
that halt or delay OA progression in a meaningful way6,13,14. Thus, there is great need for 
further scientific inquiry that aims to better understand the temporal progression of 
disease and develop efficacious disease-modifying treatment strategies for OA.  
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OA has historically been characterized by the degeneration of articular cartilage. 
In healthy joints, the highly organized and multi-phasic structure of articular cartilage 
enables its unique functional properties (Fig. 1.1)8. Articular cartilage is nearly 80% water 
by weight, the remainder of the tissue mainly consists of collagens and proteoglycans 
which make up the extracellular matrix (ECM), and chondrocytes which sparsely populate 
the ECM15. Collagen is the most abundant structural macromolecule in articular cartilage 
and accounts for nearly 60% of tissue dry weight. Type II collagen represents roughly 
90% of the collagenous ECM while minor constituents such as collagen types IX and XI 
further contribute to ECM stability through collagen crosslinking16. The highly organized 
zonal microstructure of the collagenous ECM contributes to the anisotropic tensile 
properties of articular cartilage16. The second most abundant class of macromolecule in 
articular cartilage are proteoglycans, these consist of negatively charged 
glycosaminoglycan (GAG) chains covalently bound to a protein core5,8. The negative fixed 
charged density of proteoglycans results in a swelling pressure which contributes to the 
compressive properties of articular cartilage16. Chondrocytes represent roughly 2% of 
 
Figure 1.1: Zonal cellular and microstructural composition of healthy articular cartilage. Figure 
adapted from Buckwalter, Mow, and Ratcliffe. J Am Acad Orthop Surg. 1994. 
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total cartilage volume but are thought to be the primary mediators in cartilage 
homeostasis17. Chondrocytes are largely responsible for the continued production of 
ECM components such as collagens and proteoglycans which are required for healthy 
cartilage structure and function18. Taken together, these highly organized constituents of 
articular cartilage give rise to the tissue's unique functional properties which allow for 
decades of near-frictionless joint function.  
Although OA has historically been characterized as a degenerative disease of 
articular cartilage, it is now well established that various joint tissues are altered in OA. 
For this reason, idiopathic OA is more accurately described as a whole-joint disease (Fig. 
1.2)19. For example, changes including synovial thickening and inflammation, 
subchondral bone remodeling and osteophyte formation, and neo-vascular innervation of 
joint tissues, may be observed in addition to articular cartilage degeneration19–22. To this 
date, the fundamental mechanisms that drive these changes in idiopathic OA remain 
largely unknown.  
 
 
Figure 1.2: Inflammation contributes to OA disease progression. Alterations to various joint tissues, 
and an increase in pro-inflammatory signaling contribute to the development of OA. Figure adapted from 
Kapoor+. Nat Rev Rheum. 2011. 
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1.2 Post-traumatic Osteoarthritis 
In post-traumatic osteoarthritis (PTOA) joint trauma (e.g. ligamentous rupture, 
meniscal tear, hyper-physiologic loading) precipitates the accelerated degeneration of 
joint tissues. Following traumatic joint injury, affected individuals have a nearly 10‐fold 
increased risk of developing OA-like joint changes within 10 to 20 years of injury when 
compared to their uninjured age-matched counterparts23–28. While with idiopathic OA the 
precise mechanical and/or biological changes that initiate disease are unknown, in PTOA 
the triggering events that drive pathology are known injuries. As a result, there exists a 
unique, early window of opportunity to study and treat acute changes that may ultimately 
contribute to joint degeneration, pain, and loss of function post-injury. 
Following traumatic joint injury, various disease-associated changes contribute to 
the pathogenesis of PTOA (Fig. 1.3)28. Principally, hyper-physiologic loading has been 
shown to alter chondrocyte viability, cell metabolism, and cartilage morphology within 
hours of loading induced injury29–37. Additionally, shortly following injury increased levels 
of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β), IL-6, IL-8, and tumor 
necrosis factor-alpha (TNF-α), have been reported in synovial fluid and may remain 
elevated for several months following joint trauma38–41. These pro-inflammatory mediators 
contribute to a catabolic shift in the resident cells of the joint which may have not been 
directly impacted by the initial injury28. Activation of catabolic gene sets within these cells 
leads to increased levels of proteolytic and matrix degrading enzymes such as matrix 
metalloproteinases (MMPs) and aggrecanases42,43. These enzymes directly act to 
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degrade the cartilage and subchondral bone ECM which, in turn, perpetuates the 
progression of PTOA43–49. Knock-out studies have further highlighted these pro-
inflammatory and catabolic mediators as significant contributors to disease progression 
in PTOA50. Together these data suggest that manipulation of the joint microenvironment 
following traumatic injury may impart protective effects on articular cartilage and other 
joint tissues to slow the development of PTOA. 
1.3 NF-κB activation in PTOA 
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
pathway is a rapidly inducible inflammatory signaling pathway that has been identified as 
a major player in the pathophysiology of several diseases51. Dysregulation of NF-κB is 
known to drive chronic inflammation in conditions such as irritable bowel syndrome, 
chronic inflammatory airway disease, various cancer types, and rheumatoid arthritis52–55. 
Constitutive activation of NF-κB has long been implicated in the development and 
maintenance of rheumatoid arthritis. Histologic studies of human rheumatic synovium 
 
Figure 1.3: Temporal tissue and cellular level alterations following joint injury. Acute mechanical 
joint trauma leads to a cascade of inflammatory and remodeling related cellular and tissue responses 




have shown chronically increased expression of phosphorylated p65 (P-p65) in synovial 
tissues when compared to non-arthritic joints56,57. Animal models of inflammatory arthritis 
have replicated these alterations seen in human joints and exhibit chronic activation of 
the immune system, synovial hyperplasia, neovascularization and nerve fiber sprouting 
in various joint tissues, and articular cartilage degeneration58–62. Local NF-κB activation 
in these models has also been correlated with the development of pain-sensitivity related 
behaviors63. Pharmacologic NF-κB inhibition, however, has been shown to effectively 
attenuate these pain-sensitivity related behaviors in inflammatory models64–66. 
While OA has long been classified as a non-inflammatory disease, recent studies 
have highlighted the importance of NF-κB mediated signaling and inflammation in the 
development of symptomatic PTOA following mechanical joint injury67–69. While some 
level of loading (e.g. mechanical, osmotic) helps to maintain cartilage homeostasis, 
injurious loading has been shown to rapidly induce high levels of NF-κB activation in 
chondrocytes70–73. It is thought this hyper-activation following injury contributes to a 
persistent pro-inflammatory environment that initiates NF-κB signaling in other joint 
tissues such as synovium42,70,74. Ultimately, these factors contribute to a pro-inflammatory 
and catabolic feedback loop that drives the progression of PTOA.  
Pre-clinical studies have shown NF-κB inhibition can serve to attenuate this 
positive feedback loop and protect against joint destruction75. The successful use of 
selective IκB kinase 2 (IKK-2) inhibitors, such as 8-(5-Chloro-2-(4-methylpiperazin-1-
yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide 
(PHA-408), highlight the utility of NF-κB inhibition as a disease-modifying treatment 
approach76,77. Specifically, PHA-408, a low molecular weight (560 Da), highly selective 
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inhibitor of IKK-2, has been shown to reduce the severity of inflammatory arthritis in 
multiple preclinical animal models76. However, due to the ubiquitous nature of the NF-κB 
pathway and associated off-target effects of systemic NF-κB inhibition, few drug 
candidates have been successfully implemented in the clinic78,79. Indeed, in some 
treatment applications, pathway inhibition has been found to cause adverse effects such 
as neutrophilia, fever, and increased IL-1 release51,80–82. Nevertheless, local NF-κB 
inhibition in PTOA remains a promising therapeutic approach due to the focal nature of 
the disease. For example, a phase 1 clinical trial of the IKK inhibitor, SAR113945, 
improved pain scores following intra-articular injection in patients with OA. Unfortunately, 
a phase 2a trial failed to show efficacy83. In spite of this result, there is considerable 
evidence supporting the use of NF-κB pathway inhibitors in the treatment of OA68,75,76,84–
87. 
1.4 Assessing the symptomatic progression of OA   
Although symptomatic OA imparts a substantive social and financial burden on 
society, limited research has focused on the mechanisms contributing to pain in the 
disease state88. Clinically, efforts have largely aimed to understand structural joint 
changes using radiographic based assessments89. While these methods are valuable for 
disease staging, by themselves they provide no insight into pain or joint function.  
Standardized functional and symptomatic self-reported scoring systems (e.g. 
Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Knee injury 
and Osteoarthritis Outcome Score (KOOS)) have helped to better quantify the 
symptomatic effects of OA90. Studies that have used these scoring systems paired with 
clinical imaging measures have provided valuable insight into the relationships between 
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joint structure changes, such as synovitis and the formation of bone marrow lesions, and 
symptomatic OA91,92. However, these methods still fail to directly assess the molecular 
and cellular changes contributing to symptomatic OA. 
The use of OA animal models for the study of symptomatic OA serves to address 
some limitations of clinical studies. Principally, animal models allow for the coincident and 
well controlled interrogation of molecular, cellular, structural, and functional sensitivity 
changes within the same subject93. This approach, which may be infeasible in a clinical 
setting, allows for a more comprehensive understanding of the factors influencing 
symptomatic disease progression. Indeed, OA animal models have replicated many of 
the structural changes seen in symptomatic OA (e.g. synovitis, joint effusion, bone 
marrow lesions, sensory nerve fiber innervation)58,94–100. Furthermore, these structural 
changes observed in OA models have been associated with the development of clinically 
relevant symptoms such as mechanical allodynia and functional limitations to 
ambulation101–103. Animal models have also helped uncover molecular and functional 
signaling changes in the peripheral nervous system which are thought to contribute to the 
painful symptoms of OA104,105. Nevertheless, further research into the temporal 
progression of pain-sensitivity related behaviors and functional disability in OA animal 
models may provide an improved basis for the treatment of symptomatic disease.  
Most widely utilized small animal models for the study of OA employ surgical 
means to induce joint destabilization, thus they are more accurately categorized as PTOA 
models106. Surgically induced injuries, such as those used by the destabilization of the 
medial meniscus (DMM) or anterior cruciate ligament transection (ACLT) models, 
ultimately lead to reproducible and progressive degeneration of joint tissues over time106–
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108. However, the temporal development of symptomatic disease, with implications for 
altered pain-sensitivity related behavior, remains unclear in these models. While 
standardized surgical procedures are described in the literature, surgically induced 
injuries can be technically challenging and rely on surgical expertise for consistent 
outcomes30. This may, in part, explain the variability in the onset and severity of pain-
sensitivity related behavioral alterations observed in surgical models109–114. Furthermore, 
surgical incision related factors cannot be ruled out as contributors to alterations in pain-
sensitivity related behaviors, particularly at acute timepoints115,116. Consequently, surgical 
PTOA models may be limited in their ability to study pain-sensitivity related behavioral 
alterations shortly following injury113,116–118. 
Non-invasive models of PTOA allow for the study of joint injury triggered alteration 
to pain-sensitivity behaviors without the confounding nature of a surgical incision. These 
models also enable fine-tune control of injury severity depending on loading configuration, 
duration, and magnitude29,119–121. To date, few studies have focused on the 
characterization of symptomatic disease progression following these non-invasive 
injuries, and those that have, utilize differing metrics of pain-sensitivity and behavior69,122–
126. For example, Anderson and colleagues have shown transient gait alterations following 
a non-invasive knee joint injury, however, no further changes in animal behavior were 
observed126. Others have demonstrated unilateral changes to allodynia, hyperalgesia, 
and static weight bearing shortly following non-invasive injury, but the temporal 
progression of these changes remains unclear and largely unstudied69,124. For these 
reasons, further research to interrogate the temporal presentation of pain-sensitivity 
10 
 
related behaviors following non-invasive joint injury would add value to our current 
understanding of the symptomatic progression of PTOA. 
1.5 Current treatment strategies for OA 
There are currently no clinically available therapies that safely treat both the 
symptomatic and structural aspects of OA127,128. Palliative treatments, such as non-
steroidal anti-inflammatory drugs (NSAIDs), are the most widely utilized front line 
therapies to treat the symptoms of OA129. Although NSAIDs may elicit short-term 
improvements in pain and function, their chronic usage can lead to cardiovascular and 
gastrointestinal complications130,131. 
When NSAIDs provide no palliative benefit, intra-articular corticosteroid 
administration is a common next step in treatment132. While this approach has shown 
some efficacy in reducing acute pain and inflammation, long-term outcomes are not 
improved by intra-articular corticosteroid delivery133. This may be due to the rapid 
clearance of low molecular weight solutes from the joint, intra-articular half-lives of 
corticosteroids are rarely found to exceed 12 h134. Some data also suggest high 
corticosteroid concentrations may negatively impact cartilage homeostasis by reducing 
chondrocyte ECM biosynthesis135. 
Viscosupplements, such as hyaluronic acid derivatives, have a long history of 
clinical use to treat symptomatic OA, and several formulations (e.g. Gel-One, Euflexxa, 
Orthovisc) have been granted FDA approval for intra-articular delivery136,137. These 
viscosupplements are thought to improve synovial fluid quality and reduce frictional 
coefficients in the joint138. High molecular weight hyaluronan has also been shown to 
display anti-inflammatory and immunosuppressive properties139,140. This is in contrast 
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with the inflammatory and immune-activating properties of low molecular weight 
hyaluronic acid fragments141. Despite the short-term palliative effects of these treatments, 
they still fail to substantively modify the long-term structural and symptomatic progression 
of OA132,142. Given the lack of success for these current OA treatment strategies, there is 
an unmet need for the further development of disease-modifying OA drugs128. 
1.6 Intra-articular drug delivery and clearance 
While systemic delivery of disease-modifying OA drugs has shown efficacy in many 
pre-clinical studies, systemic drug administration does not ensure ideal drug 
bioavailability in the affected joint134. Molecular entry into the joint space is size-
dependent. Smaller molecules (<10kDa) may diffuse through synovial capillaries and 
synovial intima and equilibrate within the synovial fluid (Fig. 1.4)143. Larger molecules 
undergo size-dependent sieving and have reduced access to the joint space144,145. 
Locally delivered treatment, via intra-articular injection, serves to maximize drug 
bioavailability within the diseased joint. The increased bioavailability of locally 
 
Figure 1.4: Factors influencing molecular efflux from the joint. Alterations to composition and 
structure of synovial tissues and cartilage contribute to altered clearance kinetics from OA joints. Figure 
adapted from Brown+. Acta Biomat. 2019. 
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administered drugs enables an overall reduction in drug dose which, in turn, reduces 
systemic exposure and the risk for off-target effects146. 
Following size-dependent entry into the joint, molecular efflux shows a similar size 
dependence. Small molecules, like acridine orange (370 Da), have short intra-articular 
half-lives (t1/2~30 min), whereas larger macromolecules such as hyaluronic acid (3.0x106 
Da) are cleared more slowly (t1/2~24 h)147–151. Intra-articular half-lives for NSAIDs and 
soluble steroids cluster around 1 to 4 h. These values illustrate the challenges facing 
intra-articular therapy, especially for chronic or progressive conditions where sustained 
drug concentrations are required for therapeutic efficacy152. 
There are however various biophysical phenomena that can be exploited to 
overcome some of the hurdles of intra-articular drug delivery153. For example, recent 
research has revealed the importance of charge-based interactions between locally 
delivered molecules and negatively charged cartilage ECM. Bajpayee and Grodzinsky 
have shown positively charged macromolecules exhibit enhanced molecular diffusivity 
and residence times within healthy cartilage ECM154. This effect of cationic potential in 
cartilage targeting is not without its limitations155. Specifically, supercharged-GFP 
variants, modified to have increased cationic electrostatic potential, had improved 
cartilage permeability at lower, but non-zero, net charges. Interestingly, chondrocyte 
uptake was enhanced in variants with increased cationic charge156. These results suggest 
drug biophysical properties should be carefully considered when assessing the joint 
tissue and resident cell targeting potential of intra-articular therapeutic approaches157. 
Disease related changes to other joint structures also play a role in the clearance 
of locally delivered molecules. Most notably, synovial thickening is thought to reduce 
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molecular efflux from the intra-articular space22. Despite the presence of increased 
vascularization in arthritic joints, literature consistently suggests functionally impaired 
clearance of multiple solutes20,147,158–160. Radiolabeling studies were the first to highlight 
these alterations with disease and revealed significantly reduced intra-articular clearance 
rates of 123I and 131I-labeled human serum albumin (66.5 kDa) in patients with OA159,161. 
Similar disease associated changes to intra-articular clearance have been observed in 
PTOA animal models147,160. Altered lymphatic structure and function have also been 
implicated in modulating intra-articular clearance in diseased joints162. Surprisingly, 
functional deficits in lymphatic mediated clearance are despite increased lymphatic vessel 
formation reported in arthritic joints163–167. Research by Doan and colleagues has also 
demonstrated the clearance modulating role of knee joint innervating venous and 
lymphatic vascular structures in the absence of disease151. 
Taken together, these findings reveal the benefit of intra-articular drug delivery for 
the treatment of OA and further emphasize the wide variety of factors that influence 
molecular transport from arthritic joints. When assessing and/or modulating molecular 
efflux from the joint, special care must be taken in considering the full array of parameters 
that are known to impact intra-articular transport phenomena. 
1.7 Engineered drug delivery strategies for OA 
Engineered drug delivery strategies primarily seek to overcome the clearance 
based limitations of small molecule and protein delivery to the joint. Historically, hydrogel 
and particle based drug depots have been the most widely utilized carriers for intra-
articular therapies152,168. These approaches heavily rely on the fundamental molecular 
weight based clearance properties that largely govern molecular efflux from the joint148. 
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Despite the seeming simplicity of this phenomenon, its exploitation has resulted in 
increased intra-articular residence times for locally delivered drugs through the use of 
particle and hydrogel based sustained release drug depots138,169,170. Clinical application 
of these depots (e.g. Lipotalon, Zilretta/FX-006) have prolonged the palliative effects of 
locally delivered drugs138,171–175. 
While a wide variety of drug delivery depots have been shown to improve intra-
articular residence times and the subsequent therapeutic efficacy of locally administered 
drugs, polymeric microparticles are generally thought to be better suited for intra-articular 
delivery due to their high degree of tunability176. Specifically, polymeric particles can be 
synthesized with larger diameters, when compared to lipid or dendrimer based particles, 
which help to increase their passive size-based retention within the joint170,177. 
Furthermore, synthetic and natural polymeric depots can deliver a diverse set of cargo 
(e.g. siRNA, virus, protein, imaging agents, small molecules) with a high degree of control 
over drug release and particle degradation kinetics178. 
The research in this dissertation employs both synthetic and natural polymeric 
microparticles synthesized with amphiphilic PEG-block-PLGA copolymer and silk fibroin 
(SF), respectively. Prior work has shown PEG-PLGA drug depots can efficiently 
encapsulate small hydrophobic drugs and persist in the joint for up to 4 weeks following 
intra-articular injection179,180. SF, derived from the Bombyx mori silkworm, has high 
biocompatibility, non-immunogenic degradation products, and is FDA approved in some 
biomedical applications181. Depending on processing conditions, SF biomaterial 
properties (e.g. pore size, stiffness, beta-sheet content, degradation kinetics) can be fine-
tuned for use in different applications and have shown the ability to entrap and release 
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compounds of various physiochemical properties182,183. Specifically, low molecular weight 
hydrophobic compounds, such as Rhodamine B, have been previously incorporated into 
SF microparticles with high loading efficiencies and favorable extended release 
profiles183. Furthermore, our group has shown SF microparticles serve to increase intra-
articular dwell times of low molecular weight cargo184. Given these characteristics of PEG-
PLGA and SF microparticles, and their successful use in sustained release drug depot 
applications, they were selected as favorable polymeric microparticle candidates for the 
sustained release of the hydrophobic small molecule IKK-2 inhibitor, PHA-408. 
1.8 Sensory neuron signaling and imaging 
While functional assessments of peripheral sensitivity (e.g. von Frey and 
Hargreaves tests) are valuable in assessing pain-sensitivity changes resulting from 
disease or injury, these methods alone do not provide direct insight into functional 
signaling alterations at the cellular level185–187. Sensory neurons, which consist of a cell 
body/soma, axon, and peripheral axon terminals/receptors, innervate peripheral tissues 
and are responsible for receiving and transmitting sensory input188. These afferent fibers 
relay unipolar sensory signals in response to thermal, chemical, pressure, and noxious 
stimuli through spinal nerves to the dorsal root ganglion (DRG)189. DRGs contain the cell 
bodies of sensory neurons which further transmit sensory stimuli to the dorsal horn of the 
spinal cord190. Although the basic structure and function of DRG neurons have are well 
characterized, the mechanisms by which sensory stimuli are encoded and transmitted by 
these cells remain unclear191. Therefore, a better understanding of signal transduction 
within DRG neurons is required. 
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Typical in vitro methods for the functional assessment of DRG neuron excitability, 
such as whole cell patch clamping, require surgical removal of the DRG via axotomy 
followed by subsequent enzymatic and mechanical disruption192,193. While this is useful 
for preparing DRG neurons for monolayer culture, such techniques substantially modify 
the native cellular microenvironment by reducing physiologically relevant cell-cell and cell-
matrix interactions that modulate cellular excitability in vivo194,195. Furthermore, patch 
clamping and similar current or voltage querying methods are limited to measuring 
changes in individual cells at any one time191,196. While similar approaches, such as extra-
cellular single unit recordings, may assess cellular in situ electrophysiology with minimal 
tissue disruption, these techniques still have limited throughput which may impact their 
ability to accurately represent heterogeneous cell populations189. Nevertheless, these 
tissue preparations and electrophysiological methods remain the gold standard for 
understanding ion channel dynamics191. 
Recent advancements in imaging have allowed for the simultaneous capture and 
analysis of ion and ion channel dynamics in diverse cell populations197. Fura-2 has been 
the most widely utilized fluorescent dye for this purpose198. However, Fura-2 and similar 
ultra-violet excited dyes are often not suitable for long-term or repeat analysis of ion 
dynamics due to ultra-violet induced phototoxicity197,198. Additionally, the use of 
exogenous fluorescent dyes are somewhat restricted in intact tissues due to dye loading 
and diffusion based limitations197. The development of genetically encoded calcium 
indicators (GECIs), such as those from the GCaMP family, enable spatiotemporal control 
of cell-type specific indicator expression199. These genetically encoded indicators of 
neuronal activity when paired with high speed imaging allow for the study of cell signaling 
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dynamics with minimal chemical or mechanical disturbance to the native cellular 
environment200. The research in this dissertation uses these recent advances in imaging 
and genetic techniques to develop a novel imaging modality to assess the excitability of 
sensory neurons within acutely isolated intact DRG tissues. 
1.9 Dissertation structure and aims 
1.9.1 Aim 1: NF-κB-mediated effects on behavior and cartilage 
pathology in a non-invasive loading model of post-traumatic 
osteoarthritis (Chapter 2) 
To better understand the temporal activation of NF-κB and its relation to the 
development of symptomatic PTOA following knee joint injury, a murine non-invasive 
tibial loading model of PTOA was used. Emphasis was placed on outcome measures that 
track longitudinal changes to pain-sensitivity related behavior as well as concurrent NF-
κB activation via in vivo bioluminescent imaging. Findings in Chapter 2 highlighted the 
temporal relationship between joint injury, NF-κB activation, and the development of pain-
sensitivity related behaviors. In addition, Chapter 2 results were used to define a 
therapeutic treatment window, which in turn was used to test the therapeutic efficacy of 
locally delivered PHA-408 following joint injury in Aim 2.  
1.9.2 Aim 2: Intra-articular delivery of an NF-κB inhibitor in a non-
invasive loading model of post-traumatic osteoarthritis (Chapter 
3) 
Given the involvement of the NF-κB pathway in the development of PTOA, it was 
hypothesized that acute local pharmacologic NF-κB inhibition would slow the progression 
of PTOA following joint injury. In Chapter 3 the same longitudinal outcome measures of 
pain-sensitivity and NF-κB activation, described in Chapter 2, were used to evaluate the 
efficacy of locally delivered PHA-408 following joint injury. Work also characterized and 
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explored the effectiveness of two drug depots for the sustained release of PHA-408. 
Findings in Chapter 3 highlighted the early chondroprotective effects of local PHA-408 
administration following mechanical joint injury. Modest improvements in pain-sensitivity 
related outcomes with repeated drug treatment were also observed. Nevertheless, local 
delivery of PHA-408 failed to prevent the long-term degeneration of articular cartilage. 
While engineered drug depots showed the potential for sustained drug release, their use 
did not improve measured outcomes following joint injury. 
1.9.3 Aim 3: Electric field stimulation for the rapid functional 
assessment of alterations to intact dorsal root ganglion neuron 
excitability (Chapter 4) 
Sensory neuron signaling is required for the sensation of physical stimuli. Yet, 
many aspects of sensory excitability, particularly in intact tissue, remain unclear. The 
primary goal of this aim was to describe and validate the development of an ex vivo 
imaging approach to functionally assess sensory neuron excitability within intact dorsal 
root ganglion tissues. Results showed the described novel imaging method was 
reproducible and that cells responded to applied electric field amplitudes in a voltage 
dependent manner. Electric field stimulated responses were also shown to be, in part, 
driven by tetrodotoxin-sensitive voltage-gated sodium channels. Finally, this novel 
method was used in a proof of concept study to assess excitability of sensory neurons 
following peripheral nerve injury. With injury, neurons had reduced sensitivity to electric 
field mediated stimuli, furthermore, ex vivo observations were correlated with in vivo 
assessments of peripheral sensitivity. Ultimately, these methods may help to further 
interrogate the neurophysiologic basis of sensory neuron signaling and guide the 




NF-κB-mediated effects on behavior and cartilage 




As discussed in Chapter 1, OA is one of the leading causes of disability in the 
United States. Approximately 12% of all patients seeking treatment for symptomatic OA 
have had prior joint trauma1. Following traumatic joint injury, roughly half of affected 
individuals will develop post-traumatic osteoarthritis (PTOA) within 10-20 years24,26. 
Pathological changes following traumatic joint injury are varied but may include alterations 
to joint mechanics, inflammation, cell death, and altered extracellular matrix properties28. 
Many of these changes, which occur shortly following injury, are thought to play a pivotal 
role in initiating the long-term development of symptomatic PTOA30,39–41. A better 
understanding of these acute post-injury changes, and their relationship to the 
development of symptomatic disease, may help to define optimal strategies for 
therapeutic intervention in PTOA. 
Pre-clinical animal models of arthritis serve as a useful tool for understanding the 
pathophysiology of disease108,201,210,202–209. Generally, these models may be classified by 
their means of initiation which may include chemically, surgically, non-invasively/overuse, 
and genetically induced arthritis30,106. Within each of these categories, there are an 
assortment of models that produce arthritis at varying severities and over differing 
timescales. In this work, we have chosen to use a non-invasive loading model of PTOA 
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to study behavioral changes that occur following an acute traumatic joint injury. This 
model was selected for its consistent and reproducible injury, disease-severity tunability 
(dependent on loading parameters), and the non-invasive nature of the procedure. 
Furthermore, the mechanism of injury initiation, overloading induced joint instability, is 
relevant to a large number of clinical PTOA cases.  
Loading models accurately capture many of the features of traumatic joint injury 
which may lead to PTOA in humans30. Following injurious tibial compression, knee joints 
exhibit rapid alterations to joint biomechanics, synovium, cartilage, and 
bone29,30,42,73,207,208,211,212. Knee joint loading has been shown to trigger robust NF-κB 
activation in cartilage and synovium within hours of injury68. Inflammatory signaling 
mediated via NF-κB is thought to play a crucial role in the development of PTOA51,67,75. 
NF-κB activation following injury has also been directly implicated in the development of 
chronic pain-related sensitivity63,66,213–215. Thus, further work to define the role of NF-κB 
signaling in the symptomatic progression of PTOA is warranted.  
In this chapter, our goal was to longitudinally examine the relationships between 
the development of pain-related behavioral changes and NF-κB activation in vivo in a 









2.2.1 Animal and injury model  
All procedures were performed with approval of the Washington University 
Institutional Animal Care and Use Committee. Transgenic FVB.Cg-Tg(HIV-
EGFP,luc)8Tsb/J mice (Fig. 2.1A) (The Jackson Laboratory, Bar Harbor, ME) were 
acquired (male, 9-12 weeks of age) and acclimated to testing equipment for 1 week216. 
Mice in cohort 1 were randomly assigned to sham control (CTRL, n=5) or joint injury (INJ, 
n=6). An additional group of mice (male, 9-12 weeks of age, n=5/group) were used to 
assess how knee joint injury influenced gait (section 2.2.8). To induce joint injury, mice 
were anesthetized under isoflurane (1-3% inhalation, 2 L/min oxygen) and right knees 
were loaded as previously described by Rai and colleagues on a materials testing system 
(Instron ElectroPulse E1000, Norwood, MA)29. Briefly, tibiae were positioned vertically 
with the knee upwards in deep flexion between custom-made fixtures and were then 
subjected to 60 cycles of 12 N axial compressive load (54 N/sec with 10 sec hold at 0.5 
N between cycles). This protocol reproducibly induced a sudden drop in the axial force 
recorded on the time-force curve and increased anterior-posterior joint laxity (Fig. 2.1B,C) 
via a joint laxity test in a separate cadaveric test cohort (Appendix A, Supplementary 
Methods)29,119,207. CTRL animals were placed within the test frame and their knees were 
subjected to 10 min of static axial compressive load at 0.5 N. Animals were returned to 






2.2.2 In vivo luminescence imaging of NF-κB activity 
To assess local NF-κB activation following joint injury, in vivo bioluminescent 
imaging was performed. At each imaging timepoint (Fig. 2.1D) mice received an injection 
of D-luciferin (150 mg/kg i.p., Sigma-Aldrich, St Louis, MO). Mice were anesthetized 10 
minutes following D-luciferin injection and whole-body luminescent images were acquired 
with an in vivo imaging system (10 sec exposure, IVIS 50, PerkinElmer, Waltham, MA). 
NF-κB-driven luminescence was quantified in both ipsilateral and contralateral knees 
within an 8x10 mm elliptical region of interest (ROI) that was placed around the knee joint. 
 
 
Figure 2.1: Study design. (A) Representative NF-κB response element of FVB.Cg-Tg(HIV-EGFP, 
luc)8Tsb/J mice. (B) Custom-made mount for in vivo loading to induce non-invasive joint injury and 
corresponding time versus force and displacement curves showing one cycle of compressive loading 
with characteristic one-time mid-cycle drop in the time versus force curve coinciding with ligament injury. 
(C) Injured joints have increased anterior-posterior joint laxity as measured by a joint laxity score. (D) 
Study timeline showing repeated imaging and behavioral assessments. Mean±SD (n=10/group), Mann 
Whitney test; ***=p<0.001. 
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2.2.3 Pain-related hindpaw sensitivity 
Mechanical allodynia was evaluated in both the ipsilateral and contralateral 
hindpaws using von Frey filaments. Filaments ranging from 0.02-2.0 g were applied to 
the plantar region of a stationary, non-rearing, animal using the Chaplan “up-down” 
method186,217. Briefly, the starting filament (0.4g) was applied for 3 sec or until the animal 
had a positive paw-withdrawal response (guarding, paw flick, lick, and/or jump seen in 
Fig. 2.2A). Based on the prior response either the next weaker (positive response) or 
stronger (negative response) filament was then applied. Following the first change in 
response four additional filament applications were applied (using the up-down method). 
Provided no change in response occurred, filaments were applied until the weakest or 




Figure 2.2: Graphical overview of select behavioral assessments. Representative still images of 
positive withdrawal responses (arrowpoint) for von Frey (A) and peripheral thermal sensitivity (B) 






2.2.4 Pain-related hyperalgesia 
The threshold for contact hyperalgesia was tested at the knee joint using a small 
animal algometer (SMALGO, Bioseb, Vitrolles, FRA). Mice were scruffed with one hand 
and the hindpaw was held with the knee at a ~30° flexion angle. The tip of the SMALGO 
force transducer was applied to the lateral aspect of the knee at ~30 g/sec until the animal 
showed an escape response (flinch, head jerk, and/or squeak, to a maximum of 400 g)218. 
Three independent measurements were obtained and averaged for each hindlimb on 
each mouse on all behavioral testing days. One animal within the INJ group showed 
extreme hypersensitivity/discomfort to light knee palpation on days 2 and 8 following 
loading and thus was excluded from hyperalgesia testing on those days. 
2.2.5 Hindpaw thermal sensitivity 
Mice were gently scruffed and the plantar side of the tested paw was placed on a 
hot/cold plate (50/0°C, BIO-CHP, Bioseb) while the other paw was placed on a room 
temperature plexiglass surface at the same height. Mice were held stationary until a clear 
paw withdrawal occurred or a 20 or 30 sec threshold was reached on the hot and cold 
plate, respectively (Fig. 2.2B)219. Latency to withdrawal was recorded and three 
independent measures were collected for each hindpaw at each temperature. Animals 
were allowed a one minute recovery period between consecutive hindpaw 
measurements. 
2.2.6 Static weight bearing 
Mouse hindlimb static weight bearing was measured using an incapacitance meter 
(BIO-SWB-TOUCH-M, Bioseb). Mice were placed in a small transparent enclosure with 
their hindpaws resting on two independent force plates and their forepaws resting on an 
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angled wall of the enclosure. Independent force measurements from both hindpaws were 
collected simultaneously over a 3 sec interval. Three independent measurements were 
obtained and averaged for each mouse on all behavioral testing days. 
2.2.7 Spontaneous activity 
Freely selected activity was assessed by tracking mouse movement within a 
custom arena (40 cm x 40 cm x 40 cm, matte black P95 acrylic, TAP Plastics, Stockton, 
CA) for 30 min during the dark portion of a 12 h light-dark cycle; all tracking was performed 
without the presence of investigators or other personnel and with illumination by red 
light220,221. Movement was recorded (Sony Handycam HDR-CX405, Sony Corp, New 
York, NY) and each 30 min video was analyzed (EthoVision, Noldus, Wageningen, NLD) 
to determine the difference in distance traveled, average speed, and percent time 
stationary from baseline for each animal. 
2.2.8 Spatiotemporal gait testing 
A separate cohort of mice underwent longitudinal spatiotemporal gait testing to 
determine how non-invasive knee injury alters joint function during free, unprompted, 
ambulation. A modified custom-built gait arena (Fig. 2.2C; 76 cm long x 7 cm wide x 13 
cm tall, extruded acrylic, TAP Plastics) was used to acquire spatiotemporal gait data as 
described previously222–224. During gait collection, animals voluntarily explored (i.e. not 
forced/prompted) the arena at self-selected velocities and recordings were collected with 
a high-speed video camera (FASTCAM Mini UX50, Photron, San Diego, CA) at 1000 
frames per sec. Trials with consistent walking speed and at least three complete gait 
cycles were analyzed. Longitudinal gait data were collected 2, 7, 14, and 36 days 
following joint injury. Spatiotemporal gait parameters including duty factor, duty factor 
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imbalance, and spatial symmetry were calculated using Automated Gait Analysis Through 
Hues and Areas (AGATHA) open source software223–226. 
2.2.9 Histology  
Mice were euthanized at the terminal timepoint (113 days) and ipsilateral knees 
collected for histology. All knees were fixed in 4% paraformaldehyde for 48 h, decalcified 
for 72 h using ImmunocalTM (Fisher Scientific, Waltham, MA), immersed in 30% w/v 
sucrose for 24 h, and cryoembedded in Tissue-Tek® O.C.T. (Sakura Finetek, Torrance, 
CA). Serial coronal sections (8 µm) of ipsilateral knees from all groups were acquired, 
and one section representing the most severe evidence of arthritic changes was chosen 
for staining with H&E, Safranin O, and fast green. Stained sections were graded to 
consensus by two blinded graders using the Osteoarthritis Histopathology Assessment 
System (OARSI) within the medial and lateral femoral condyle (MFC/LFC) as well as the 
medial and lateral tibial plateau (MTP/LTP)227. 
2.2.10 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad 
Software, La Jolla, CA). A repeated measures two-way ANOVA with Bonferroni’s post-
hoc was used to test for differences between CTRL and INJ at each timepoint for all 
longitudinal measures. In vivo imaging and 50% withdrawal threshold data were log-
transformed (base 10) to better meet ANOVA assumptions. A repeated measures two-
way ANOVA with Bonferroni’s post-hoc was used to test for differences in cartilage 
OARSI scores at each cartilage site between CTRL and INJ groups. The relationship 
between NF-κB luminescence and allodynia was tested via Pearson correlation on log-
transformed (base 10) data (Appendix A, Supplementary Methods). For velocity 
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dependent gait parameters a linear regression was fit to CTRL animals and residual 
values were calculated225,226,228,229. Following, a two-way ANOVA with Bonferroni’s post-
hoc was used to test for differences in gait outcomes at each timepoint between CTRL 




2.3 Results  
2.3.1 Joint injury leads to increased NF-κB-driven luminescence 
A transient increase in NF-κB-driven luminescence was observed in INJ ipsilateral 
limbs when compared to ipsilateral limbs from CTRL mice on days 1 and 3 following joint 
injury (Fig. 2.3A,B). Within injured ipsilateral limbs, luminescence intensity peaked within 
the knee ROI on day 3 and decreased thereafter. There was no evidence of differences 
in NF-κB-driven luminescence in the contralateral joints between CTRL and INJ animals.  
2.3.2 Joint injury alters sensitivity to evoked mechanical but not 
thermal stimuli  
Non-invasive joint injury resulted in several changes to pain-related sensitivity and 
behavior in mice. Increased hindpaw sensitivity to mechanical stimuli (allodynia) was 
observed following joint injury as evidenced by a reduced 50% hindpaw withdrawal 
threshold at days 2, 8, and 15 following joint injury (Fig. 2.3C). Following day 15, the 50% 
withdrawal threshold in the INJ group returned to levels that were consistent with those 
in the CTRL group, although a reduced 50% hindpaw withdrawal reemerged in the INJ 
group on day 113. There were no differences between 50% withdrawal thresholds of 
CTRL and INJ groups within contralateral hindpaws. Within a 4 week period following 
loading, several animals in INJ group exhibited promoted guarding in their ipsilateral 
hindpaw. In some animals, this behavior persisted for the remainder of the study. 
Furthermore, increased NF-κB signaling was associated with reduced withdrawal 
thresholds in the first week of the study (Fig. 2.3D).  
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Joint injury also led to transient hyperalgesia in the ipsilateral limbs of animals in 
the INJ group; reduced hyperalgesia thresholds were observed on days 2 and 8 following 
joint injury compared to animals in the CTRL group (Fig. 2.3E). There were no observed 
differences in hyperalgesia thresholds for contralateral limbs between mice in the CTRL 
and INJ groups. 
 
 
Figure 2.3: Non-invasive joint injury alters NF-κB signaling and sensitivity to mechanical stimuli. 
(A and B) Increased luminescent signal (arrowpoint) was apparent in ipsilateral INJ knees 1 and 3 days 
following joint injury (C=contralateral). (C) Mice in the INJ group had increased mechanical sensitivity in 
their ipsilateral hindpaw following injury. (D) Increased NF-κB signaling in joints was associated with 
reduced withdrawal thresholds in the first week of the study. (E) Mice in the INJ group had a reduced 
threshold to noxious mechanical stimuli in their ipsilateral, but not contralateral, knee following joint 




Withdrawal latency from a hot (Fig. 2.4A) or cold (Fig. 2.4B) thermal stimuli at the 
hindpaw were not found to differ between CTRL and INJ groups. Within groups, response 
latencies were similar in ipsilateral and contralateral limbs (Appendix A, Fig. A.1), 
generally, latencies were also found to decrease over the course of the study.
 
Figure 2.4: Thermal sensitivity at the hindpaw. Non-invasive knee joint injury did not alter sensitivity 
to a hot (A, 50°C) or cold (B, 0°C) stimulus at the hindpaw. C=contralateral, repeated measures two-




2.3.3 Joint injury alters non-evoked behaviors  
Mice in the INJ group exhibited reduced weight bearing on their ipsilateral hindlimb 
on days 2 and 8 following joint injury (Fig. 2.5). For the remainder of the study weight 
bearing between CTRL and INJ groups were equivalent.  
Animals in the INJ group showed a trend of reduced freely selected activity on day 
2 following joint injury, corresponding trends in average speed and percent time stationary 
were also observed (Fig. 2.6A-D). Ambulatory levels within individual mice, particularly 
within the CTRL group, were quite variable throughout the study, additionally, ambulation 








Figure 2.5: Static weight bearing. Static weight bearing on the ipsilateral limb was transiently reduced 




Several gait parameters were transiently altered with joint injury. Duty factor (Fig. 
2.7A), stride length, and stance width were linear related to animal velocity, therefore, 
residuals were used for the analysis of these data. Due to inconsistent gait patterns (e.g. 
hopping and non-weight bearing) 2 days following joint injury, animals of the INJ group 
could not undergo digitization using AGATHA software. One week following joint injury 
animals in the INJ group had a reduced ipsilateral hindpaw duty factor residual and a 
corresponding increased duty factor residual for their contralateral hindpaw (Fig. 2.7B,C). 
This imbalance between hindpaws was sustained until day 14 post-injury (Fig. 2.7D). 
Forepaw duty factors were not influenced by hindpaw injury (Fig. 2.7E,F). There were 
also no observed differences in animal walking speed between groups following joint 
injury (Fig. 2.7G). Spatial symmetry, which highlights unilateral imbalances in the 
step:stride length ratio, was altered one week following injury in hindpaws only (Fig. 
2.7H,I). No differences were observed in fore or hindlimb measures of stance width or 
bilateral measures of step length (data not shown). 
 
Figure 2.6: Non-invasive joint injury results in a modest reduction to spontaneous activity. (A) 
Representative open field centroid traces of CTRL and INJ mice. (B-D) Following INJ mice showed a 
transient trend of decreased distance traveled and corresponding alterations to average speed and 













Figure 2.7: Non-invasive joint injury alters spatiotemporal gait parameters. (A) Duty factor is 
dependent on velocity, concentric squares highlight reduced ipsilateral hindlimb duty factor 7 days post 
INJ. (B and C) Individual hindlimb duty factor residuals (C=contralateral) and hindlimb duty factor 
imbalance (D) were transiently altered following injury. (E and F) Forelimb duty factors and animal 
velocity (G) were not altered by joint injury. Hindlimb gait became spatially asymmetric (H), no spatial 
alterations to gait were observed in the forelimbs (I). Repeated measures two-way ANOVA w/ 




2.3.4 Joint injury leads to histological development of PTOA  
 Grading of articular cartilage revealed significant damage to select joint regions 
following joint injury. Knee joints from animals of the INJ group showed evidence of severe 
articular degeneration in the medial compartment of the joint compared to knee joints from 
the CTRL group (Fig. 2.8A,B); median OARSI scores in MFC were 0.5 and 6 in CTRL 
and INJ joints respectively (p<0.001), median scores within the MTP were 1.75 in CTRL 
and 6 in INJ joints (p<0.01). In several cases, complete loss of cartilage on the MFC and 
MTP was observed at the terminal timepoint. The LFC and LTP of animals in the INJ 
group had median OARSI grades of 3 and 1.5, respectively, compared to median scores 
of 0.5 and 1 in CTRL joints. Qualitatively, knee joints of the INJ group showed signs of 
inflammation, fibrosis, synovial hyperplasia, and osteophyte formation when compared to 
joints from the CTRL group. 
  
 
Figure 2.8. Long-term degenerative changes to articular cartilage following injury. (A) 
Representative histology shows full thickness articular defects in injured knee joints 113 days following 
injury (B) INJ knees had elevated OARSI scores in the medial femoral condyle (MFC) and medial tibial 
plateau (MTP), scale bar = 500 µm. LFC=lateral femoral condyle, LTP=lateral tibial plateau. Repeated 




 In this work, we showed non-invasive knee joint injury in mice led to both transient 
and long-term pain-related sensitivity and behavior changes consistent with those seen 
in humans following acute traumatic joint injury28. Specifically, injury induced NF-κB 
activation within the knee joint was associated with the onset of pain-related sensitivity, 
gait alterations, weight bearing imbalances, and cartilage degeneration. Together these 
data provide novel insight into the temporal progression of symptomatic disease within 
this non-invasive murine model of PTOA. 
We and others have previously shown injection models of inflammatory arthritis 
result in transient changes to peripheral sensitivity following joint injury63,93,220. Similarly, 
surgical destabilization models of PTOA consistently result in hindpaw allodynia when 
compared to sham operated animals; however, the onset, presentation, and duration of 
this mechanical allodynia is varied and different from that observed in this non-surgical 
PTOA model103,109,113,230. For example, Temp and colleagues showed mice experience a 
biphasic pain-sensitivity phenotype following medial meniscus transection113. Specifically, 
acute allodynia primarily attributed to surgery resolved within one week and a second 
onset of allodynia was observed four weeks after surgery. Withdrawal thresholds within 
this second pain-sensitivity phase were of similar magnitude to those observed within the 
one week post-surgery window. These results are in contrast to those reported within this 
study; following non-invasive injury we observed sustained allodynia for two weeks. At 
later timepoints withdrawal thresholds remained slightly lower in INJ ipsilateral hindpaws, 
however, these thresholds were never as low as those observed in the two week post-
injury period. Recent work by Heegde and colleagues corroborates the findings of the 
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current study and shows that mechanically-induced joint injury is associated with a 
transient and early onset of hindpaw allodynia124. 
In addition to the development of chronic allodynia, we report a transient decrease 
in the mechanical threshold to noxious stimuli at the injured knee joint. This acute 
unilateral alteration is contrary to the chronic mechanical hyperalgesia observed following 
surgically induced destabilization of the medial meniscus218. The mechanisms that 
contribute to these pain-related sensitivity alterations in differing models of PTOA remain 
unknown. Further scientific inquiry should aim to shed light on the phenotypic changes to 
sensory neurons that innervate structures within the injured knee joint; these studies may 
better delineate the mechanistic differences in pain-sensitivity between PTOA 
models105,231. In this study no bilateral sensitivity alterations were observed following 
injury. This may suggest a lack of bilateral changes to the peripheral and central nervous 
system following mechanically induced joint injury. This is in contrast to observations 
made in injection models of inflammatory arthritis which have shown increased bilateral 
expression of neuropeptides such as substance P and calcitonin gene related peptide in 
the dorsal root ganglia and dorsal horn of the spinal cord shortly following injury232,233. 
These changes have been reported to be influenced by commissural spinal interneuron 
crosstalk and increased systemic levels of pro-inflammatory cytokines234. To date, there 
have been no reports of increased systemic pro-inflammatory cytokines within this non-
invasive model of PTOA. 
 A novel finding of this study highlighted the early changes to non-evoked behaviors 
of activity in gait/ambulation and weight bearing imbalance in stance. Prior studies have 
not characterized the temporal progression of such behavioral changes following non-
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invasive joint injury109,110,126. Anderson and colleagues showed slight alterations (6% 
reduction in duty factor for ipsilateral hindpaws and corresponding, but non-significant, 
7.3% increase in duty factor for the contralateral hindpaw) to gait parameters 1 day 
following non-invasive joint injury126. In this study, we were unable to characterize 
changes shortly following joint injury due to severe gait abnormalities including limb 
disuse. Despite this, gait alterations one week post-injury appeared to be larger, with a 
14.7% reduction in ipsilateral hindpaw and 9.9% increase in contralateral hindpaw duty 
factor, respectively. Furthermore, alterations were sustained for two weeks (-3.9% and 
+3.5% for ipsilateral and contralateral hindpaws, respectively) following joint injury. This 
may suggest that the temporal progression of factors influencing behavioral alterations 
are only just beginning 1 day following injury and more severe behavioral 
phenotypes/abnormalities are present at slightly later timepoints within one week of knee 
joint injury. Additionally, this study utilized a freely selected gait assessment as opposed 
to the forced treadmill running assessment used by Anderson and colleagues which may 
further explain these observed differences. Others have shown similar transient 
alterations to gait following chemically, genetically, and surgically induced 
arthritis109,110,230,235,236. 
By 3 weeks following joint injury CTRL and INJ groups appear to be similar in most 
behavioral measures assessed in this study. This is despite persistent alterations to joint 
morphology and mechanics (e.g. development of osteophytes, cartilage lesions, synovial 
hyperplasia, reduced range of motion)29–31,68,211. With that said, these findings point to 
consistent changes in behavior under conditions that minimize animal fatigue and 
external stresses. Mice are widely believed to temporarily mask pain-related behaviors 
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during periods of prompted stimulation or stress such that activity changes associated 
with freely selected behaviors may be of particular value to understanding symptomatic 
joint pathology in murine models122. Future studies might benefit from assessments that 
allow for quantification of freely selected behaviors including animal rearing, running 
wheel use, and place preference122,237. With this in mind, a careful understanding and 
pairing of complementary behavioral tests that assess different aspects of pain-related 
sensitivity in disease are important for accurate and consistent characterization of 
symptomatic profiles in animal models of PTOA.  
 In vivo bioluminescent imaging enabled longitudinal quantification of bulk NF-κB 
pathway activation following knee joint injury. Data suggested that early NF-κB signaling 
was correlated (Appendix A, Fig A.3) with the acute and chronic presentation of hindpaw 
allodynia. Early increases in NF-κB-driven luminescence were also associated with more 
severe cartilage erosion at the terminal timepoint (Appendix A, Fig. A.4). These data 
suggest acute NF-κB signaling following injury may be predictive of the symptomatic and 
structural progression of PTOA. The week long elevation in NF-κB-driven luminescence 
observed in this study is in contrast to changes observed following surgically induced 
knee joint injury. In studies using surgically induced PTOA models, joint injury has been 
shown to elicit a prolonged elevation in NF-κB-driven luminescence for up to 6 
weeks118,238. This suggests the systemic effects of surgery, with consequences for the 
prolonged elevation of inflammatory mediators, may elicit sustained alterations in joint 
inflammation and associated pain-related sensitivity in these widely utilized surgical 
models of PTOA. It is therefore imperative to consider these factors when comparing 
outcomes across differing pre-clinical animal models of PTOA.  
39 
 
In conclusion, the non-invasive model of PTOA described in this study may be 
valuable for studying the early pathological changes following acute traumatic joint injury 
and how they relate to pain-related sensitivity and behavioral changes without the 
confounding nature of a surgical incision. Nevertheless, further work to better dissect the 
temporal development and presentation of pain and sensitivity alterations in PTOA should 
be performed to help direct future treatment strategies that may prevent both the 
histological and painful progression of disease. 
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Intra-articular delivery of an NF-κB inhibitor in a non-




In Chapter 2 we showed that acute NF-κB activation within the knee joint was 
coincident with increased mechanical sensitivity at the hindpaw. Additionally, we showed 
that transient activation of NF-κB was associated with the development of several other 
evoked and non-evoked behavioral changes that were not observed following sham 
loading within the control (CTRL) group. Longitudinal in vivo imaging of NF-κB activation, 
as described in Chapter 2, allowed us to determine an appropriate window for therapeutic 
intervention following joint injury. In this chapter, we sought to inhibit NF-κB signaling in 
the knee joint following injury via various local delivery strategies.   
Increased NF-κB activity has been implicated in the development of pain following 
peripheral injury and recent data suggest NF-κB may be directly responsible for 
sensitization in some pain-related ion channels213–215. Furthermore, human studies have 
shown that patients with worsening symptomatic OA have increased mRNA and protein 
level expression of p-65, MMPs, and IL-1β within the knee joint239. NF-κB activation via 
inflammatory mediators has also been shown to play a causal role in the increased 
production of neurotrophic factors such as nerve growth factor (NGF)240. Indeed, these 
neurotrophic factors are known to induce further context dependent NF-κB signaling and 
play a pivotal role in injury induced sensitization241,242. Additionally, these factors have 
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been observed at high concentrations in synovium and cartilage following joint injury58,243–
251. While aberrant NF-κB signaling is thought to drive the excessive production of pro-
algesic factors in symptomatic OA, many studies have sought to elucidate the role of 
these pro-algesic molecules independently of NF-κB252–254. While these approaches have 
shown analgesic benefits in arthritic patients adaptation of therapies, such as tanuzamib, 
beyond clinical trials has been limited due to long-term deleterious effects on cartilage 
and bone252,255,256. Therefore, strategies that target pain and inflammatory signaling 
pathways via alternative mechanisms are of interest in the disease-modifying treatment 
of symptomatic OA.  
Given the role of NF-κB activation in the development of OA, it has been identified 
as a promising druggable target for the treatment of disease. Pre-clinical studies have 
shown protective effects of selective IκB kinase 2 (IKK-2) inhibitors, such as 8-(5-Chloro-
2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-
benzo[g]indazole-3-carboxamide (PHA-408) (Fig. 3.1), highlighting their potential as 
disease-modifying OA drugs76,77. Specifically, PHA-408, a low molecular weight (560 Da), 
highly selective inhibitor of IKK-2, has been shown to prevent the development of 
inflammatory arthritis in streptococcal cell wall and lipopolysaccharide preclinical animal 
models76. Furthermore, direct inhibition of the NF- κB signaling pathway has been shown 
to have analgesic benefits following inflammatory injuries66,257–259. However, off-target 
effects upon systemic delivery and rapid clearance of small molecules from the joint 
following intra-articular delivery have limited their therapeutic effect51,260. The proven 
efficacy of IKK-2 inhibitors when administered systemically motivates the development of 
sustained release intra-articular delivery strategies for the treatment of OA. These 
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strategies may help to reduce the deleterious effects of repeated systemic administration 
and prolong drug residence times within the joint.  
Sustained release drug depots have shown promise in clinical translation for the 
treatment of OA175,261. Poly(lactic-co-glycolic) (PLGA), is FDA approved, and has long 
been utilized as a polymeric drug carrier for its tunable sustained drug release 
characteristics; however, acidic breakdown products from the polymer are known to lead 
to inflammation. Amphiphilic block polymers combining polyethylene glycol (PEG) and 
PLGA can efficiently encapsulate small hydrophobic drug molecules for sustained 
release. These block polymers also have reduced inflammatory effects due to the 
incorporation of PEG which serves to mask the inner PLGA core180. Prior work has shown 
that PEG-PLGA microparticles can remain entrapped in the synovial cavity for up to 4 
weeks following intra-articular injection179. Similarly, silk fibroin (SF) microparticles have 
been shown to improve joint residence times of locally injected drugs by nearly 4-fold 
 
Figure 3.1: NF-κB canonical signaling and PHA-408. The canonical NF-κB pathway can be activated 
by many protein-receptor interactions which ultimately leads to phosphorylation of IKKβ/IKK-2 and 
subsequent phosphorylation of the endogenous super-repressor of NF-κB, IκBa. The now heterodimeric 
p65/p50 complex can translocate to the nucleus, binds its consensus sequence(s), and upregulate 
transcription of pro-inflammatory as well self-regulatory gene sets. PHA-408 selectively inhibits IKK-2 
phosphorylation and thus prevents downstream pathway activation. 
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when compared to non-particle formulations184. SF also exhibits limited immunogenicity, 
tunable temporal bioresorbable characteristics, and the potential for sustained release of 
low molecular weight hydrophobic drugs183,262. 
In Chapter 3, work aimed to investigate the disease-modifying potential and 
biodistribution of locally delivered PHA-408 following non-invasive mechanical joint injury. 
Additionally, we formulated and explored the efficacy of PEG-PLGA and SF 
microparticles for the sustained release of PHA-408 to determine if a single intra-articular 
dose of a sustained release preparation may influence the development of symptomatic 
PTOA. 
3.2 Methods 
3.2.1 Joint injury and drug delivery  
All procedures were performed with approval of the Washington University 
Institutional Animal Care and Use Committee. Transgenic FVB.Cg-Tg(HIV-
EGFP,luc)8Tsb/J mice (male, 9-12 weeks of age) were used in the four animal cohorts 
described in this chapter. 
A preliminary study was used to determine intra-articular PHA-408 dosing. In this 
work, mice received a single intra-articular injection of mono-iodoacetate (0.1 mg/5 µL, 
MIA) and two subsequent intra-articular injections of PHA-408 (0.1 µg/ 5 µL, n=4) or 
vehicle (saline+0.1% DMSO, n=3) at 0 and 48 h following MIA injection. Drug treatment 
had minimal impact on joint localized NF-κB signaling (Fig. 3.2A). However, early delivery 
of PHA-408 reduced hindpaw allodynia (Appendix B, Fig. B.1) and appeared to have 
modest protective effects on articular cartilage one month following MIA injection (Fig. 
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3.2B,C). Based on these data, PHA-408 dosing was increased in hopes of reducing 
localized NF-κB-driven luminescence66. 
To first determine the efficacy of local NF-κB inhibition following mechanical joint 
injury, mice were randomly assigned to naive (CTRL, n=4), joint injury (INJ, n=6), or joint 
injury plus treatment (INJ/Tx, n=5) groups. Following joint injury, as described in Chapter 
2, mice received a single intra-articular injection of PHA-408 (3 µg/5 µL, sterile saline + 
0.1% DMSO, Alchem Pharmtech Inc, Monmouth Junction, NJ) or vehicle (sterile saline + 
0.1% DMSO) and were sacrificed 48 h post-injury (Fig. 3.3) to study the immediate cellular 
effects of joint injury and drug treatment on articular cartilage (described in Section 3.2.6).  
A separate cohort of mice was used to test for drug related effects using 
longitudinal measures described in Chapter 2. Mice from cohort 1 (Chapter 2) were 
randomly assigned to joint injury plus treatment (INJ/Tx, n=5). Animals in the INJ/Tx group 
received two intra-articular injections of PHA-408 (3 µg/5 µL), one immediately following 
injury and another 48 h post-injury. 
 
Figure 3.2: Preliminary data suggested intra-articular administration of PHA-408 protects against 
cartilage degeneration in an inflammatory model of arthritis. Following administration of mono-
iodoacetate (0.1 mg, MIA) mice received vehicle (Veh) or PHA-408 (0.1 µg, Tx) injections (0 and 48 h 
post-MIA injection). (A) Tx knees showed minimal alteration to NF-κB-driven luminescence when 
compared to Veh injected knee joints. (B) Veh treated joints showed loss of Safranin-O staining in the 
lateral tibial plateau (arrowhead) whereas Tx (C) joints did not 4 weeks following MIA injection. Scale 
bar = 500 µm. Repeated measures two-way ANOVA. 
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To test the effect of a sustained release drug formulation, mice in cohort 3 received 
a single intra-articular injection of PHA-408 loaded PEG-PLGA microparticles (INJ/TxMP, 
3 µg/5 µL; synthesis described in Section 3.2.3), PHA-408 (1 µg/5 µL), or vehicle (in vivo 
imaging n=2-5 group/timepoint; hindpaw sensitivity n=2 group/timepoints) and were 
tracked for 1 week to assess changes in NF-κB-driven luminescence and hindpaw 
sensitivity. Finally, to test the biodistribution and clearance behaviors PHA-408 (described 
in Section 3.2.7), mice in cohort 4 received two intra-articular injections of PHA-408 (3 
µg/5 uL) or vehicle (0 and 48 h) following knee joint injury (n=2-5 per group/timepoint). 
3.2.2 Gene expression 
Gene expression was assayed using qPCR on an Applied BiosystemsTM 
StepOnePlusTM Real-Time PCR System (Software v2.3, Foster City, CA). Briefly, 
immortalized human synovial sarcoma cells (SW982, ATCC, Manassas, VA) were 
seeded (300,000 cells/well) on a 6-well plate and allowed to grow until 90% confluency 
(37°C, 5% CO2). Cells were then co-treated with recombinant human interleukin-1 beta 
(1 ng/mL; IL-1β, R&D Biosystems, Minneapolis, MN) and PHA-408 (0.1 to 10 µM). 
Following a 6 h incubation period, cells were lysed using RLT buffer (Qiagen, Hilden, 
 
Figure 3.3: Study timeline. Behavioral assessments and timepoints mimic those described in Chapter 
2. Mice in INJ/Tx group received two intra-articular injections (5 min and 48 h) following joint injury, mice 
in the INJ/TxMP group only received one intra-articular injection 5 min following joint injury. Mice used 
for in situ live-dead imaging were sacrificed (*) 48 h following joint injury and received only one intra-
articular injection. Mice used for biodistribution and clearance studies were sacrificed (*) 30 min, 2, 72, 
or 168 h following joint injury. 
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DEU) + 1% mercaptoethanol. RNA isolation was performed using the QIAGENTM Mini kit 
(Qiagen). Briefly, samples were homogenized using a QIAshredderTM column and RNA 
was then bound to an RNeasy spin column. The sample was then washed, and DNA was 
digested using DNAse I. RNA was eluted with RNAse-free water and RNA concentration 
and purity were determined using the 260/280 ratio in a NanoDrop™ system 
(ThermoFisher, Waltham, MA). RT-PCR was performed using the iScript cDNA Synthesis 
Kit (BioRad, Hercules, CA). qPCR was used to detect amplification of tumor necrosis 
factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) (Applied Biosystems, 
Foster City, CA) using ΔΔCt; GAPDH and ACTB were used as housekeeping genes and 
data were normalized to untreated controls. 
3.2.3 PEG-PLGA microparticle formulation 
PEG-PLGA microparticles were fabricated using a coaxial microfluidic phase 
separation method by Dr. Era Jain263. A 2% w/v PEG-b-PLGA (PEG 2kDa, PLGA 
11.5kDa, Sigma-Aldrich, St. Louis, MO) solution prepared in dichloromethane (DCM) was 
flowed through an inner needle (31 G) at 0.2 mL/h and a 5% w/v polyvinylalcohol (PVA) 
solution was passed through an outer concentric needle (16 G). PEG-PLGA droplets were 
collected in a TeflonTM bath in 5% w/v PVA under constant stirring. Following washing 
and sieving (70 μm nylon filter) microparticles were vacuum dried and stored. Drug loaded 
microparticles were prepared by adding PHA-408 to the DCM/PEG-PLGA (1:10 
drug:polymer ratio) phase prior to microparticle preparation. Microparticles were imaged 
and their average diameter was calculated by measuring ≥100 microparticles per 




3.2.4 Silk fibroin microparticle formulation  
Silk fibroin (SF) solution was prepared as previously described181,264. Briefly, whole 
silk cocoons were cut into dime sized pieces and boiled in 0.025M sodium bicarbonate 
for 30, 60, or 120 min for sericin residue removal. Silk was then washed (20 min, 3X, 
diH2O) and allowed to dry overnight. Dried silk was solubilized in 9.3M lithium bromide 
(4h, 60°C) at a 20% w/v ratio. The solution was transferred into a dialysis cassette 
(MWCO 3500, Thermo Scientific) and dialyzed against 5 L of diH20 for 48 h with constant 
stirring, water was exchanged every 12 h. Dialysate was then removed and centrifuged 
(Sorvall Evolution RC, Thermo Fisher) at 12,700 RCF (20 min, 4°C) to remove aggregates 
and debris. The solution was diluted to a final 6% (w/v) solution with diH2O and stored at 
4°C. 
SF microparticles were prepared by mixing 3 mL extracted SF (30, 60 or 120 min) 
with 12 mL of 5% PVA (1:4 silk:PVA ratio) and casting the mixture in a polystyrene petri 
dish (100 mm) to form a film. The film was re-suspended in diH2O and microparticles 
were washed, centrifuged, and lyophilized. PHA-408 loading was performed post 
microparticle synthesis by mixing PHA-408 in ethanol (EtOH, 2 mg/mL) with 
microparticles (1:10 drug:microparticle ratio) for 3 days under constant stirring. EtOH was 
then allowed to evaporate, microparticles were subsequently washed with EtOH, 
lyophilized, and stored at 4°C. Microparticle synthesis was performed by Dr. Burcin Yavuz 
at Tufts University. 
3.2.5 In vitro release and drug bioactivity  
For quantification of drug release via high performance liquid chromatography 
(HPLC) 10 mg of PHA-408 loaded microparticles were incubated with 1 mL of phosphate 
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buffered saline (PBS), pH 7.4 at 37°C. At regular time intervals PBS was collected and 
an equivalent volume of fresh PBS was added. Samples were stored at -80°C for later 
analysis. Collected aliquots were analyzed via HPLC (Agilent 1200 system, Agilent 
Technologies, Santa Clara, CA) to measure released PHA-408. HPLC analyses were 
performed by Dr. Burcin Yavuz at Tufts University. Following extraction in dimethyl 
sulfoxide (DMSO) samples were run through an Agilent Poroshell 120 EC-C18 column 
(2.7 μm, 4.6mm×50mm, Agilent Technologies) at 25°C. A mobile phase of 
methanol:water with 0.1% trifluoroacetic acid (60:40) was used at a flow rate of 0.75 
mL/min and UV absorption was measured at 260 nm. Drug concentration in aliquots was 
determined by comparison to a standard curve. 
To determine drug bioactivity following release from microparticles, PHA-408 
loaded microparticles (10 mg/mL) were suspended in Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, and 
placed in a TranswellTM insert at 37°C. At regular time intervals, aliquots of media 
incubated with PHA-408 loaded microparticles were collected and an equivalent volume 
of fresh media was added to each TranswellTM. NF-κB inhibition from released PHA-408 
in microparticle incubated media was measured using a SW982 reporter cell line 
transduced with lentivirus carrying an NF-κB luciferase response element construct 
(pHAGE NFκB-TA-LUC-UBC-GFP-W, Addgene, Watertown, MA)265. Following 
transduction (1 µL, 4.3 multiplicity of infection), cells were plated and allowed to attach. 
Media was then supplemented with 1 ng/mL of recombinant human interleukin-1 beta (IL-
1β, R&D Biosystems, Minneapolis, MN) to induce an inflammatory response as measured 
by increased luciferase expression in the transduced cells. Some wells received dosing 
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with an aliquot of media incubated with PHA-408 loaded microparticles as described 
above, and the luminescence signal was measured following a 24 h incubation period 
(Enspire, PerkinElmer) using Bright-GloTM (Promega, Madison, WI). Bioluminescence 
values were normalized to IL-1β only treated controls. 
3.2.6 In situ live-dead cellular imaging 
 Intact femurs from animals in cohort 2 were harvested 48 h following joint injury for 
in situ live-dead imaging (Fig. 3.4A-C). Knees were grossly dissected from mice by cutting 
through the mid-femoral diaphysis. Muscle and connective tissue were then removed 
from the around the knee joint, patellar tendon and medial/lateral collateral ligaments 
were transected, and the knee joint was disarticulated via tensile overload. Care was 
taken to avoid any contact with articular cartilage and samples were continuously irrigated 
with hypertonic (400 mOsm) media during dissection266,267. Jeweler forceps were used to 
remove medial and lateral menisci as well as posterior/anterior cruciate ligament 
 
Figure 3.4: In situ live-dead imaging setup. Following staining, intact femurs where placed atop a 
#1.5 coverslip and fixed in custom holder (A) such that the femoral shaft was positioned at a ~30° angle 
with respect to the x-axis and both condyles made complete contact with the coverslip as shown from 
the sagittal plane. (B) Representative coronal histology section and (C) corresponding max intensity 
projections (100µm z-stack) of fluorescence images show cell nuclei in the articular cartilage of both the 
lateral (left) and medial (right) femoral condyles (LFC/MFC) in the transverse imaging plane, scale bar 




remnants. Cleaned femurs were stained with Hoechst 33342 (10 µM, ThermoFisher), 
Calcein-AM (5 µM, Invitrogen, Carlsbad, CA), and Propidium Iodide (PI, 5 µM, 
ThermoFisher) for 1 h at 37°C34,43,268. Following staining, intact femurs were imaged 
(FV1200, Olympus, Tokyo, JPN). Z-stacks (100 µm thickness) were acquired of each 
femoral condyle. Hoechst+ and PI+ cell number per condyle was determined via an 
automated thresholding-based ImageJ script. 
3.2.7 Biodistribution of PHA-408 following intra-articular injection 
Mice (n=2-5 per group/timepoint) in cohort 4 underwent compressive joint injury 
followed by intra-articular injections of either PHA-408 (3 µg/5 µL) or vehicle (5 µL) 
immediately following and 48 h post-injury. At terminal timepoints (30 min, 2 h, 3 d, 7 d) 
1 mL of blood was collected by cardiac puncture and serum was obtained following 
centrifugation. Lymph nodes (inguinal and lumbar), knees, and urine were collected at 
the time of sacrifice269,270. Lymph nodes were suspended in 500 µL acetonitrile (ACN), 
and homogenized (Mini-BeadBeaterTM, BioSpec, Bartlesville, OK). Knees were flash 
frozen in liquid nitrogen, homogenized (BioPulverizerTM, BioSpec), and suspended in 2 
mL of ACN. Samples were then vortexed for 2 h and centrifuged to collect clarified ACN. 
Drug concentrations in serum, urine, lymph nodes, and knee tissue were estimated via 
LC-MS upon an Agilent 1200 series HPLC instrument and an Agilent 6410 triple-
quadruple mass spectrometer operated in positive electrospray ionization mode (collision 
gas flow rate: 11 L/min, source block temperature: 300°C). Samples (20 µL) were injected 
into a C18 column (4.6×100 mm, 3.5 μm, Agilent) at 37°C using a gradient elution method 
(Water and ACN mix) at a flow rate of 0.65 mL/min. PHA-408 was quantified by multiple 
reaction monitoring (Q1/Q3, 560.246/514.113) with a 51V collision energy. LC-MS 
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analyses on ACN extracted tissues were performed by Dr. Burcin Yavuz at Tufts 
University. High levels of background signal were detected in lymph nodes of vehicle 
injected mice, thus a noise floor was defined for lymph node tissues (mean+2*SD, vehicle 
injected mice).  
3.2.8 In vivo luminescence imaging of NF-κB activity 
To assess local NF-κB activation following joint injury, in vivo bioluminescent 
imaging was performed as described in Chapter 2, Section 2.2.2.  
3.2.9 Pain-related hindpaw sensitivity 
The effects of local NF-κB inhibition on the development of mechanical allodynia 
following joint injury were using von Frey filaments as described in Chapter 2, Section 
2.2.3. 
3.2.10 Pain-related hyperalgesia 
The threshold for contact hyperalgesia was tested at the knee joint using a small 
animal algometer as described in Chapter 2, Section 2.2.4. 
3.2.11 Hindpaw thermal sensitivity 
Hindpaw thermal sensitivity to hot and cold stimuli were tested using methods 
previously described in Chapter 2, Section 2.2.5. 
3.2.12 Static weight bearing 
Alterations to static weight bearing were assessed using methods described in 





3.2.13 Spontaneous activity 
Freely selected activity during the animal dark cycle was tracked as previously 
described in Chapter 2, Section 2.2.7. 
3.2.14 Histology  
Following sacrifice (113 days post-injury), ipsilateral knees were collected for 
histology and processed as described in Chapter 2, Section 2.2.9. Stained sections were 
graded to consensus by two blinded graders using OARSI scoring227.  
3.2.15 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad 
Software, La Jolla, CA). A one-way ANOVA with Dunnett’s post-hoc was performed to 
test for differences in ΔΔCt values in SW982 cells, all comparisons were made to IL-1β 
only treated controls. A repeated measures two-way ANOVA with Bonferroni’s post-hoc 
was used to test for differences in Hoechst+ and PI+ cell counts between CTRL, INJ, and 
INJ/Tx femoral condyles. A repeated measures two-way ANOVA with Bonferroni’s post-
hoc was used to test for differences between INJ and INJ/Tx groups at each timepoint for 
all longitudinal measures. In vivo imaging and 50% withdrawal threshold data were log-
transformed (base 10) to better meet ANOVA assumptions. A repeated measures two-
way ANOVA with Bonferroni’s post-hoc was used to test for differences in cartilage 
OARSI scores at each cartilage site between INJ and INJ/Tx groups. Statistical 




3.3 Results  
3.3.1 PHA-408 effectively reduced IL-1β induced inflammatory 
signaling in vitro 
The small molecule inhibitor of IKK-2, PHA-408, reduced inflammatory signaling 
following co-stimulation with IL-1β in vitro. Shortly after stimulation with the inflammatory 
mediator IL-1β, PHA-408 treated cells showed a reduction in transcriptional levels of the 
inflammatory and immunomodulatory genes TNF-α, IL-6, and IL-8 (Fig. 3.5A-C).    
3.3.2 Characterization of an NF-κB reporter cell line  
 Transduced SW982 cells expressed GFP in a viral titer dependent manner (Fig. 
3.6A). Furthermore, transduction was stable following multiple passages (Fig. 3.6B) and 
IL-1β stimulated NF-κB-driven luminescence showed a dose (Fig. 3.6C) and time 
(Appendix B, Fig. B.2) dependent decrease with PHA-408 mediated NF-κB inhibition. 
 
 
Figure 3.5: Micromolar concentrations of PHA-408 effectively reduce IL-1β induced inflammatory 
signaling in vitro. PHA-408 treated cells showed reduced mRNA level of TNF-α (A), IL-6 (B), and IL-8 (C) 
when compared to non-drug treated IL-1β stimulated cells. One-way ANOVA with Dunnett’s post-hoc; 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. 
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3.3.3 Local delivery of PHA-408 exhibits chondroprotective effects 
shortly following joint injury 
 Shortly following joint injury an increase in PI staining was observed in fluorescent 
images of the MFC (Fig. 3.7A). Cell numbers in the mid-contact region of femoral condyle 
articular cartilage, as assessed by Hoechst+ staining, were not different between groups 
(Fig. 3.7B). Injured knee joints had an increased number of PI+ cells within the MFC when 
compared to CTRL; however, PI+ cells were reduced in INJ/Tx MFCs when compared to 
untreated INJ MFCs (Fig. 3.7C).  
 
Figure 3.6: Characterization of NF-κB luciferase reporter cell line. SW982 cells were transduced 
with an NF-κB responsive lentivirus at varying viral concentrations. (A) Increasing viral concentration 
led to increased levels of GFP+ cells when assessed via fluorescence microscopy (top) and flow 
cytometry (bottom). (B) Cells remained stably transduced with passaging (1 µL virus, green box 
represents mean±SD at P0). (C) NF-κB-driven luminescent shows a dose dependent response with 






Figure 3.7: Short-term chondroprotective effect of PHA-408 following loading. (A) Representative 
maximum intensity projected images of the medial femoral condyle (MFC) from each group. (B) No 
differences in lateral femoral condyle (LFC) or MFC cell number were observed 48 h post joint injury. 
(C) INJ led to an increase in PI+ cells in the MFC, however, INJ/Tx MFC PI+ cell count was reduced 
when compared to INJ only. Scale bar = 100 µm, compass rose: L=lateral, A=anterior, M=medial, 
P=posterior. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc; **=p<0.01, ****=p<0.0001 
vs CTRL; #=p<0.05 INJ vs INJ/Tx. 
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3.3.4 Characterization of PEG-PLGA and SF microparticles and in 
vitro drug release  
 PEG-PLGA microparticles had an average diameter of 11.9±7.6 µm (Fig. 3.8A,C) 
and a 37% drug loading efficiency (final drug loading ratio 1:27, drug:microparticle). PEG-
PLGA microparticles exhibited sustained release characteristics with limited burst release 
in vitro, their estimated drug release half-life was 19.7±3.2 days (Fig. 3.8D). Furthermore, 
100% of loaded drug was eventually released from PEG-PLGA microparticles into PBS 
release buffer as particles degraded.  
 SF microparticles had an average diameter of 13.4±7.1 µm (Fig. 3.8B,C) and drug 
loading efficiencies of greater than 99% across all formulations (final drug loading ratio 
1:10, drug:microparticle). SF microparticles showed the potential for sustained release 
for over two months in vitro; however, only ~10% of loaded PHA-408 was released from 
SF microparticles into PBS release buffer in all formulations (Fig. 3.8D). The average SF 
microparticle drug release half-life was 16.2±2.4 days.   
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PHA-408 released from both PEG-PLGA and SF microparticles remained 
bioactive and effectively inhibited IL-1β induced NF-κB signaling in a reporter cell line 
(Fig. 3.8E). NF-κB inhibition from microparticle conditioned media was similar to inhibitory 








Figure 3.8: Characterization of PEG-PLGA and SF microparticles. Representative bright field (A) 
and SEM (B) images of PEG-PLGA and SF microparticles, respectively. (C) Size distribution of PEG-
PLGA and SF drug loaded microparticles. All particle formulations showed continuous release of PHA-
408 for 80 days (D) and PHA-408 released from microparticles showed sustained inhibition of IL-1β 
induced NF-κB activation in SW982 reporter cells (E), inhibition was near levels seen with 10 µM of free 





3.3.5 Local delivery of PHA-408 following joint injury has modest 
effects on NF-κB activity and animal behavior  
 Locally delivery of PHA-408 following joint injury did not significantly alter the 
transient rise of NF-κB-driven luminescence within injured knees; however, NF-κB activity 
was elevated in INJ/Tx joints 14 days following knee joint injury when compared to INJ 
untreated joints (Fig. 3.9A,B). The development of allodynia shortly following injury was 
similar in INJ and INJ/Tx groups (Fig. 3.9C). Withdrawal thresholds in the INJ/Tx group 
 
Figure 3.9: Intra-articular injection of PHA-408 follow joint injury has modest effects on NF-κB 
activity and animal behavior following knee joint injury. (A and B) NF-κB activity in drug treated 
joints was elevated two weeks following joint injury. INJ and INJ/Tx animals showed similar 50% 
withdrawal (C) and escape (D) thresholds. (E) INJ/Tx mice had a more rapid recovery towards uniform 




did show a trend towards recovery at later timepoints, however, these were not 
significantly different from INJ 50% withdrawal thresholds (99/113 d, p=0.09, INJ v 
INJ/Tx). INJ and INJ/Tx groups had similar thresholds to noxious mechanical stimuli at 
the injured knee joint (Fig. 3.9D). Drug treatment improved static weight bearing in the 
INJ/Tx group 8 days following injury when compared to the INJ, untreated, group (Fig. 
3.9E). 
Alterations to free ambulation following joint injury were similar in INJ and INJ/Tx 
groups (Fig. 3.10A-C). On average, distance traveled in both groups remained below 
baseline for 8 weeks following knee joint injury.  
No alterations to thermal sensitivity at the ipsilateral hindpaw were observed with 
the presentation of a hot stimulus between INJ and INJ/Tx groups (Fig. 3.11A). 
Interestingly, animals in the INJ group had reduced latencies to withdrawal from a cold 
thermal stimulus, however, this was prior to knee joint injury and subsequent drug 





Figure 3.10: Treatment does not modify freely selected ambulation. (A) Animal matched centroid 
traces at baseline and 2 days following knee joint injury. INJ/Tx animals had similar alterations to their 
change in distance traveled (B) and percent time stationary (C) when compared the INJ group. 
Mean±SEM, repeated measures two-way ANOVA w/ Bonferroni’s post-hoc. 
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3.3.6 Drug treatment does not improve long-term articular cartilage 
outcomes 
 Drug treatment was not effective in modifying the long-term degeneration of 
articular surfaces in the joint (Fig. 3.12A,B). Similar OARSI scores were observed in INJ 
and INJ/Tx joints 16 weeks following knee joint injury (Fig. 3.12C). A trend of increased 
degeneration in the medial joint compartment was consistent between groups.  
3.3.7 PHA-408 is rapidly cleared from the knee joint following intra-
articular administration 
Due to the limited efficacy of locally delivered free PHA-408 following joint injury, 
we hypothesized short joint residence times of the low molecular weight drug might be 
 
Figure 3.11: Thermal sensitivity at the hindpaw with drug treatment. Latency to withdrawal from a 
hot (A, 50°C) thermal stimulus was not found to be different between INJ and INJ/Tx at the ipsilateral 
hindpaw. Latency to withdrawal from a cold (B, 0°C) thermal stimulus, however, was reduced at baseline 
in the INJ group. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05. 
 
 
Figure 3.12: Drug treatment does not influence long-term degenerative changes to articular 
cartilage following injury. Representative histology of INJ (A) and INJ/Tx (B) knees. (C) OARSI scores 
showed similar levels of degeneration to articular surfaces of INJ and INJ/Tx knee joints in both the 
lateral and medial compartments of the joint 16 weeks following joint injury. Repeated measures two-




contributing to the observed outcomes. Following intra-articular injection, low molecular 
weight drugs are rapidly cleared from the joint via the circulatory and lymphatic systems. 
Despite suspension based PHA-408 injections (Appendix B, Fig. B.3), drug was rapidly 
cleared from the joint space to draining lymph nodes (Fig. 3.13A). PHA-408 was detected 
within injected knee joints for 72 h following the first intra-articular injection (Fig. 3.13B). 
The estimated intra-articular half-life for PHA-408 was 41.2 min. Drug was not detected 
in knee joints one-week post-injection. Drug levels above the lower detection limit 
(Appendix B, Fig. B.4) persisted in contralateral, uninjected, limbs for 2 h following 
 
Figure 3.13: Drug biodistribution and clearance. (A) Schematic highlighting tissues removed for 
biodistribution and clearance assessments following intra-articular injection with PHA-408 (t=0 and 48 
h). Drug was rapidly cleared from (B) knee tissue, as well as (C) inguinal and (D) lumbar lymph nodes, 
(E) serum, and (F) urine following repeated intra-articular injections at t=0 h and t=48 h. Solid line=lower 




injection. Average drug concentrations within injected limbs were 17.8 µM and 4.0 µM at 
30 min and 2 h timepoints, respectively. Drug levels in major draining lymph nodes, 
serum, and urine all exhibited a rapid reduction in drug concentration with time following 
intra-articular injection (Fig. 3.13C-F).  
3.3.8 Sustained release of PHA-408 does not overtly improve 
measured outcomes over freely administered drug 
Given the rapid clearance of suspension based PHA-408, we hypothesized local 
delivery of sustained release PHA-408 loaded PEG-PLGA microparticles may elicit 
protective effects against joint injury-induced NF-κB signaling and pain-related behavioral 
changes shortly following injury. A trend of increased NF-κB-driven luminescence was 
observed in knees of INJ/Veh, INJ/Tx, and INJ/TxMP treated groups as compared to 
baseline (Fig. 3.14A). Trends in 50% withdrawal thresholds were similar in INJ/Veh, 
INJ/Tx, and INJ/TxMP groups (Fig. 3.14B). Thus, treatment with free drug or a sustained 
release preparation did not overtly resolve pain-related sensitivity or inhibit an increase in 
NF-κB activity shortly following joint injury. Furthermore, a sustained release SF 
microparticle formulation did not prolong drug residence time withing the knee joint 
following intra-articular administration (Appendix B, Fig. B.5)  
 
Figure 3.14: PEG-PLGA microparticles do not overtly improve early PTOA related outcomes. 
One-time drug treatment in soluble or MP formulation did not alter the onset of NF-κB signaling in the 




 Work in this chapter described the effects of locally delivered PHA-408 following 
knee joint injury. Data suggested treatment with PHA-408 acutely protected chondrocytes 
from injury initiated cell death. Despite these observed early effects on articular cartilage, 
PHA-408 only modestly influenced the development of pain-sensitivity related behaviors 
following knee joint injury. Furthermore, PHA-408 did not prevent the long-term 
histological development of PTOA. Finally, we showed PHA-408 loaded PEG-PLGA and 
SF microparticles provided sustained release of bioactive drug; however, local delivery of 
drug-loaded PEG-PLGA and SF microparticles, respectively, did not alter 
imaging/sensitivity outcomes or improve drug residence times within the joint following 
injury. These results highlight the challenges of translating promising small molecule drug 
candidates from in vitro development to animal models of disease. 
Shortly following knee joint injury we observed increased chondrocyte membrane 
permeability within the MFC of loaded knee joints. In comparison, changes within the LFC 
were minimal. These early differences in medial/lateral chondrocyte health aligned with 
histologic articular cartilage outcomes assessed 16 weeks following injury which showed 
increased cartilage degeneration within the medial joint compartment. We hypothesize 
acute delivery of PHA-408 following injurious loading may have reduced chondrocyte 
necroapoptosis mediated cell death72,271–273. Indeed, others have shown similar 
chondroprotective effects of NF-κB inhibition following joint injury67,68,77,164,274. 
Nevertheless, these acute protective effects were inconsequential to long term joint 
health. This may be in part due to the severity and chronic destabilizing nature of this 
injury model35,43,70,275,276.  
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Data described in Chapter 2, and prior work by Yan and colleagues, informed the 
PHA-408 dosing strategy used in this chapter. Yan and colleagues showed cyclical 
loading of the murine knee joint, albeit at a lower force amplitude of 6 N, led to robust 
phosphorylation of p65 in chondrocytes within 12 h of loading, with additional P-p65 
observed in synovium 48 h following knee joint injury68. In Chapter 2 we showed 
longitudinal NF-κB-driven luminescent signal rapidly increased in a similar timeframe 
following injurious loading. Signal peaked 3 days following knee joint injury and quickly 
returned towards baseline by day 7, where it stayed for the remainder of the study. Given 
these pathway kinetics, it seemed drug treatment immediately following injury may elicit 
favorable disease-modifying outcomes. Indeed, Yan and colleagues further showed two 
time (0 & 48 h post-injury) intra-articular administration of NF-κB inhibiting siRNA 
nanoparticles following knee joint injury modestly reduced chondrocyte expression of P-
p65, chondrocyte apoptosis, and cartilage lesion size; locally delivered siRNA also 
entirely prevented the development of knee joint hyperalgesia68,69. As eluded to 
previously, the contrasting results in observed outcomes between these studies may be 
explained by the severity of loading induced knee joint injury. While 12 N cyclic loading 
of the knee joint consistently leads to ligamentous rupture and subsequent joint 
destabilization, 6 N loading has not been reported to induce such changes29,121,207. These 
significant and long-lasting changes to joint biomechanics following 12 N injury may 
warrant an increase in drug dosing frequency and duration. To date, the long-term 
efficacy of drug treatment following the 12 N injury model used in this study has remained 
elusive142,277. However, preliminary dosing studies we performed in the MIA model of 
arthritis suggested acute delivery of PHA-408 may protect articular cartilage from MIA 
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induced changes. Together these data highlight the potential utility of infrequent/acute 
NF-κB inhibition in the absence of a persistent destabilizing injury and suggest 
alternative/additional dosing timepoints may be required following traumatic joint injuries 
that chronically alter joint biomechanics77,164,278. 
Given the chronic destabilizing nature of the injury model used in this study and 
the observed clearance kinetics of free PHA-408 from the knee joint, we hypothesized a 
sustained release drug depot might help to prolong intra-articular drug residence times 
and improve measured outcomes described in this chapter. Large polymeric micron-sized 
drug carriers have long been shown to have increased residence times when compared 
to freely administered solutes168,172,173,184. Additionally, both PEG-PLGA and SF 
microparticles have been used for the sustained release of various low molecular weight 
hydrophobic drugs making them ideal carriers for the sustained release of PHA-
408179,183,279,280. Indeed, in vitro studies showed both microparticle formulations facilitated 
the sustained release of PHA-408 and released drug showed effective inhibition of 
inflammatory mediator induced NF-κB signaling. However, preliminary results following 
the local delivery of drug loaded PEG-PLGA microparticles did not show an overt impact 
on measured outcomes shortly following knee joint injury. Furthermore, drug levels within 
the joint were below the lower detectable limit (1.99 nM) of our assay following local 
delivery of drug loaded SF microparticles. This was despite a more than 15-fold increase 
in total delivered/encapsulated drug. Given these factors, the long-term effects of PHA-
408 laden sustained release depots were not studied. 
Acute treatment with PHA-408 led to increased NF-κB-driven luminescence in 
INJ/Tx mice; although this result was somewhat surprising, similar observations have 
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been previously reported following the administration of small molecule NF-κB inhibitors, 
such as bortezomib and BAY 11-7082, in inflammatory disease states82. Given this, the 
acute effect of PHA-408 on NF-κB-driven luminescence was further explored in the 
absence of knee joint injury. Results showed intra-articular delivery of PHA-408 or vehicle 
control both led to slightly increased NF-κB-driven luminescence within injected knee 
joints when compared to contralateral knees (Appendix B, Fig. B.6), however, these levels 
were still far below those observed in INJ and INJ/Tx knees. The influence of high local 
drug concentrations may elicit cytotoxic effects which is a further concern following intra-
articular injection (Appendix B, Fig. B.7). Nevertheless, these results highlight an inability 
to inhibit bulk knee joint NF-κB-driven luminescence following local administration of PHA-
408. Based on this, and the rapid rise and subsequent fall of NF-κB-driven luminescence 
following injury, it seems possible NF-κB-driven luminescence at the whole joint level in 
this reporter mouse line is not entirely representative of signaling kinetics within relevant 
tissues such as articular cartilage and synovium. To this point Kobayashi and colleagues 
have reported increased NF-κB activation in articular chondrocytes 8 weeks following a 
knee joint destabilizing injury, this far exceeds the week long rise in signaling we observed 
in this study67. Thus, NF-κB-driven luminescence in this mouse line may have limited 
sensitivity in measuring injury and drug treatment induced changes to knee joint tissues 
and is a limitation of this longitudinal study. Future cross-sectional studies, that rely on 
histological outcomes rather than longitudinal in vivo imaging, may help to better dissect 
the spatiotemporal activation of NF-κB in specific joint tissues post-injury238. Indeed, in a 
simplified ex vivo organ culture model, we observed effective inhibition of NF-κB signaling 
with application of PHA-408 (Appendix B, Fig. B.8). In spite of the results reported in this 
67 
 
dissertation, positive structural disease-modifying effects observed in less severe PTOA 
models, such as the destabilization of the medial meniscus model, support the use of 
local NF-κB inhibition for the treatment of PTOA60,67,68,75,77,107,108,238,274,281.   
In this study intra-articular administration of PHA-408 led to modest alterations in 
pain-sensitivity related behaviors following knee joint injury. Interestingly, INJ/Tx mice 
showed a trend towards increased 50% withdrawal thresholds in their ipsilateral hindpaw 
at late timepoints within this study. This suggests acute treatment with PHA-408 following 
knee joint injury may have had some long-term effect on pain-sensitivity even following 
drug clearance from the joint. Others have shown similar peripheral sensitivity modulating 
effects of anti-inflammatory drugs following traumatic joint injury; however, little work has 
focused on the specific role of NF-κB inhibition in mediating pain-sensitivity related 
behaviors in PTOA animal models69,109,111,218,282. Early delivery of NF-κB inhibitors has 
been shown to impart similar long-lasting effects in inflammatory and neuropathic pain 
models by modulating the local inflammatory environment at the site of injury and by 
influencing the expression of nociception related proteins, such as the voltage gated 
sodium channels NaV1.7 and NaV1.8, in tissue innervating sensory neurons (Appendix 
B, Fig. B.9)64,214,257,283–286. Recent work has also highlighted the putative role P-p65 plays 
in the direct gating of NaV1.7 activity in sensory neurons215. These data suggest there is 
a role for careful modulation of NF-κB in the treatment of painful inflammatory conditions 
such as PTOA (Fig 3.15)58,215,295,287–294. 
In general, the analgesic effects of disease-modifying OA drugs are poorly 
understood. While many pre-clinical studies seek to characterize the structural influences 
of drug treatment, they often overlook drug related impacts on pain-related behaviors88. 
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In some instances, however, the opposite has been true. For example, great promise had 
been placed on the clinical development of tanezumab, a humanized monoclonal NGF 
antibody, for the analgesic treatment of knee OA, however, its widespread adaptation has 
been limited due to long-term deleterious effects on articular cartilage and bone 
quality252,255,256. Indeed, subsequently conducted animal studies have shown tanezumab 
may accelerate the onset of articular defects and osteophyte formation following joint 
injury. Presumably, degenerative changes are accelerated due to increased joint loading 
on the injured limb in the presence of the analgesic effects of tanezumab296,297. With this 
in mind, future work should simultaneously aim to better understand and treat both the 
structural and symptomatic progression of OA.  
In conclusion, the work described in this chapter showed the potential for PEG-
PLGA and SF microparticles to act as sustained release drug depots for the small 
molecule NF-κB pathway inhibitor, PHA-408. Results also highlighted the short-term 
chondroprotective effects of local PHA-408 delivery and the modest behavioral modifying 
 
Figure 3.15: Traumatic joint injury triggers a pro-inflammatory/algesic cascade which 
contributes to the symptomatic progression of PTOA. Following traumatic joint injury, local NF-κB 
activation contributes to the increased production and release of pro-inflammatory/algesic/catabolic 
molecules by the resident cells of the joint which contribute to erosive changes to joint structures. 
Increased intra-articular levels of these factors may induce nerve fiber sprouting and sensitization, in 
part, through NF-κB mediated signaling. 
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impact repeated drug treatment had on longitudinal pain-sensitivity related behavioral 
outcomes following joint injury. Drug treatment, however, did not influence the long-term 
structural development of PTOA in injured knee joints. While this study ultimately failed 
to show substantial long-term structural disease modification via local PHA-408 delivery, 
the results still provide valuable insight into the temporal development of symptomatic 
PTOA following knee joint injury. This work also highlights many of the hurdles which 
must be overcome for successful small-molecule intra-articular drug delivery. Functional 
assessments of pain-sensitivity related behaviors, such as those employed in this study, 
should continue to be utilized to better understand what factors contribute to the 
symptomatic progression of conditions such as OA. Hopefully, these approaches will help 
to inform the future development of efficacious treatment strategies that slow or halt the 
structural and symptomatic progression of musculoskeletal pathologies.  
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Electric field stimulation for the rapid functional 
assessment of alterations to intact dorsal root 
ganglion neuron excitability  
 
4.1 Introduction 
A diverse set of somatosensory neurons are required for physical perception. 
Sensations of touch, temperature, taste, and pain are all transmitted via sensory neurons, 
but the mechanisms by which these sensory stimuli are encoded and transmitted remain 
unclear. For this reason, there is great need to further interrogate the neurophysiologic 
basis of sensory neuron signaling. The functional assessment of cellular neurophysiology 
has traditionally relied on manual patch clamp based techniques191. While this approach 
remains the gold standard for understanding the electrophysiological basis of ion channel 
dynamics and action potential propagation, these methods are limiting due to their relative 
technical difficulty and low throughput189. When paired with calcium- or voltage-sensitive 
fluorescent indicators, optical imaging allows for the simultaneous capture and analysis 
of cellular signaling in diverse cell populations198. Additionally, the development of 
genetically encoded calcium indicators (GECIs), such as GCaMP6s, allows for the 
spatiotemporal control of cell-type specific calcium indicator expression298. In these 
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imaging-based approaches, calcium flux is used as a surrogate trailing measure of action 
potential propagation and can be influenced by a wide variety of ion channels (Fig. 4.1). 
Nevertheless, GECIs have given investigators the freedom to reliably study in vivo and in 
vitro neural signaling dynamics without the need for invasive patch clamping or 
exogenous dye loading199.  
 Following acute isolation of dorsal root ganglion (DRG) tissues by axotomy, in vitro 
techniques typically require DRG dissociation by enzymatic digestion and mechanical 
disruption. Prior work has shown even short-term incubation of neural cells with low-
concentration enzymatic agents, such as trypsin or papain, may reduce cell viability and 
the expression of structurally and functionally relevant proteins299. Furthermore, this 
physical disruption of native tissue architecture alters the intrinsic cell-cell and cell-matrix 
interactions that are present in vivo; indeed, these interactions have been shown to 
Figure 4.1: Sensory neuron classifications and their ion channels. Sensory neurons exit the dorsal 
horn of the spinal cord, through the dorsal root (DR). Cell soma reside in the dorsal root ganglion (DRG) 
and can be generally classified into four sub-categories by size, conduction velocity, and protein/ion 
channel expression. C-fibers are small diameter, peptidergic or non-peptidergic neurons which are 
primarily implicated in the sensing of noxious stimuli. Lightly myelinated Aδ fibers are also implicated in 
sensitivity to noxious thermal, mechanical, and chemical stimuli. Larger Aα and Aβ myelinated fibers 
are primarily implicated in proprioception and non-noxious mechanosensation. All neuron subtypes 
express a variety of ion channels (TRP, NaV, KV, CaV, etc.) which are essential for appropriate action 
potential initiation and transmission, alterations in cellular expression of these ion channels can alter 




influence neuronal excitability as well as gene and protein expression194,300,301. Long-term 
monolayer culture of DRG neurons also often requires the exogenous administration of 
growth factors, such as nerve growth factor and glial cell line-derived neurotrophic factor, 
but these have been shown to directly impact cell phenotype302–304. Extended culture 
periods following isolation have also been shown to alter cell-cell interactions through 
satellite cell proliferation; while anti-mitotic drugs may be administered in vitro to prevent 
this proliferation, their use negatively impacts sensory neuron structure and 
function305,306. These factors, amongst others, may influence neural cell responses in 
vitro. Hence, there is a need to develop alternative in vitro methods for assessing sensory 
neuron excitability in acutely isolated DRGs.  
The work in this chapter describes the development of an electric field stimulation 
mediated cellular imaging method for the direct interrogation of Ca2+ signaling dynamics 
in intact acutely isolated DRG tissues. This method allows for the rapid and simultaneous 
characterization of functional excitability in hundreds of sensory neurons. Using this 
technique, we show an ability to measure dose-dependent changes to electric field 
stimulated Ca2+ signaling in the presence of a voltage-gated sodium channel inhibitor 
and an ability to detect differences in neuronal excitability in a peripheral nerve injury 
model. Taken together, the described system shows potential for the study of 
pharmacologically and injury-induced alterations to large and heterogeneous neural 







4.2.1 Animal model 
All procedures were performed with approval of the Washington University in St 
Louis Institutional Animal Care and Use Committee. Transgenic Advillin-CreERT2 (Cre/+, 
Stock No: 032027, The Jackson Laboratory, Bar Harbor, ME) mice were crossed with 
STOP-GCaMP6s (+/-, Stock No: 028866, The Jackson Laboratory) mice298,307. Cre-
positive mice received three consecutive doses of tamoxifen (i.p, daily, 75 mg/kg, Sigma-
Aldrich, St Louis, MO) to induce GCaMP6s expression in Advillin expressing neurons 
(Fig. 4.2A,B)307. GCaMP6s was chosen for its high signal to noise ratio and slower 
temporal dynamics which enable its use in widefield, spinning-disk confocal, imaging. 
 
Figure 4.2: Experimental design. (A) Sensory neuron specific expression of GCaMP6s was attained 
by crossing STOP-GCaMP6s (+/-) and Advillin-CreERT2 (Cre/-) mice. (B) Robust GCaMP expression 
in DRG neurons was observed 3 weeks following tamoxifen (tam, 75 mg/kg, IP, 3X) dosing. (C) Intact 
DRGs were placed within an EFS recording chamber beneath a nylon mesh and were continuously 
perfused with fresh artificial cerebrospinal fluid (aCSF, 2 mL/min). (D) Representative cellular traces of 
the normalized GCaMP fluorescence (∆F/F) and corresponding images (E), with increasing voltage 
amplitude (5-100V). The inset depicts the applied excitatory pulse train that was used at each voltage 
(10 Hz, 1 ms pulse width); frames corresponding to each numbered peak are shown with color-coded 
cellular regions of interest. 
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Three weeks following tamoxifen dosing mice were utilized for electric field stimulation 
experiments. Mice were maintained on a 12-h light-dark cycle with access to food and 
water ad libitum. 
4.2.2 Dorsal root ganglion (DRG) isolation 
Mice were deeply anesthetized under isoflurane (3% inhalation, 2 L/min oxygen, 
n=6, 16-20 wks). A transcardial perfusion was performed with artificial cerebrospinal fluid 
(aCSF, 124 mM NaCl, 5 mM KCl, 20 mM HEPES, 10 mM d-glucose, 1.3 mM MgCl2, 1.5 
mM CaCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4)308 after which DRGs (T13-L5) were 
isolated via a dorsal approach196. Following a midline dorsal incision, paraspinal 
musculature, connective tissue, and fat were carefully removed with micro-dissection 
scissors to reveal the dorsal bony elements of the spine. Micro-rongeurs were then used 
to perform a multi-level laminectomy to expose the spinal cord, which was gently 
repositioned to expose the DRGs at each spinal level. Fine forceps were used to grasp 
the distal nerve root and gently remove the DRG from the neuroforamen, and spring 
scissors were used to carefully cut the nerve roots proximal and distal to the DRG. 
Isolated DRGs were then incubated in aCSF and used for EFS experiments within 8 h of 
isolation. 
4.2.3 Electric field stimulation (EFS) 
Intact DRGs were placed in the center of a recording chamber (RC-RC49MFSH, 
Warner Instruments, Hamden, CT), secured by a nylon mesh, and perfused with aCSF 
(2 mL/min) (Fig. 4.2C). Two parallel, linear platinum electrodes connected to a pulse 
generator (Grass SD9, Natus Neuro, Warwick, RI) were inserted at opposite ends of the 
recording chamber and DRGs were stimulated with bipolar square pulse waves (1 ms, 10 
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Hz, 1 sec on/ 29 sec off) at voltage amplitudes of 5-100V (Fig. 4.2D); these EFS 
parameters were chosen for their ability to evoke robust evoked Ca2+ transients within 
intact DRGs as have been reported previously190,309–311. The geometry of the recording 
chamber ensured the generation of a uniform electric field between electrodes190. Intact 
DRGs were imaged (Plan Apo λ 10X, 0.45 NA) to collect GCaMP6s fluorescence 
(488/525 nm, ex/em, 10 Hz) upon a spinning disk confocal microscope (Ti2-CSU-X1, 
Nikon Instruments, JPN) (Fig. 4.2E). Time series recordings at a single imaging plane 
(~20 µm from tissue basal surface, 2.5 µm z-thickness) were acquired. Single recordings 
were completed in 6 min; DRGs were allowed to recover within the recording chamber 
for 5 min followed by a repeated exposure to EFS in order to evaluate the repeatability of 
response and to confirm viability of tested neurons. 
4.2.4 Tetrodotoxin inhibition 
To test the ability of the described EFS imaging technique to be used for drug 
screening in intact DRGs, the potent voltage-gated sodium channel (VGSC) inhibitor 
tetrodotoxin (TTX, Tocris, Minneapolis, MN) was used as described here312. DRGs 
underwent one voltage sweep (5-100 V) as described, followed by incubation with 
increasing concentrations of TTX (5 min incubation, 0.01-10 µM), and a repeat of the EFS 
voltage sweep protocol was performed.  
4.2.5 Peripheral nerve injury 
Peripheral nerve injury was induced in female Advillin-GCaMP6s mice (16 wks, 
n=2, [Cre/+,+/-], n=2 [+/+,+/-]) as described313,314. Mice were anesthetized under 
isoflurane (1-3% inhalation, 2 L/min oxygen), and the left hindlimb was prepped with 
sterile technique. A 1 cm skin incision parallel to the femur was made at the mid-thigh to 
76 
 
expose the muscle fascia and blunt dissection was used to expose the sciatic nerve below 
the biceps femoris (Fig. 4.3A,B). The sciatic nerve was then tightly ligated with three 
ligatures (6-0 chromic gut suture), with 1 mm spacing, proximal to the sciatic (Fig. 4.3C). 
Muscle, fascia, and subcutaneous tissues were closed with 5-0 vicryl suture and skin 
closed was closed with 4-0 nylon suture. Following recovery from anesthesia animals 
were returned to their home cage (≤5 mice/cage) and allowed to freely ambulate. 
Following nerve injury, mice were aged one month prior to use in EFS experiments which 
were performed on L3-L5 DRG. 
4.2.6 Hindpaw mechanical sensitivity 
Hindpaw sensitivity to light-touch was evaluated bilaterally using von Frey 
filaments as described in section 2.2.3.  
4.2.7 Hindpaw thermal sensitivity 
Hindpaw sensitivity to a hot stimulus (55°C) was tested using methods previously 
described in section 2.2.5. 
 
Figure 4.3: Peripheral nerve injury. (A) Anterior view of left hindlimb (B) The biceps femoris (BF) was 
bluntly dissected and retracted (arrowhead) to expose the sciatic nerve (ScN), which was tightly ligated 
proximal to ScN trifurcation. (C) Chromic gut sutures were resorbed 4 weeks following surgery; however, 
ligation sites and tissue damage were readily observed upon dissection (arrowheads). (QF=quadriceps 
femoris, GM=gluteal muscles). Figure adapted from Kochi+. Plos One. 2013. 
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4.2.8 Data analysis 
Following stimulation of DRGs in the EFS chamber, digital images of DRG 
responses were compiled into high-speed video format. Within a single frame 
corresponding to the period preceding EFS stimulation, manual tracing of all visible cell 
bodies was performed in ImageJ (NIH, Bethesda, MD). Fluorescent intensity values within 
each cell region of interest (ROI) over time were exported and analyzed using a custom 
MATLAB (MathWorks, Natick, MA) script. Briefly, fluorescent signal prior to each EFS 
stimulation was used to calculate baseline fluorescence within each cell ROI (F0). This 
baseline value was used to calculate ∆F/F0, where ∆F is the rise in fluorescence due to 
EFS at each stimulation voltage. A piecewise cubic interpolating polynomial was used to 
correct for drift in baseline fluorescence with time prior to each stimulus using the local 
minimum (F0) within each ROI prior to EFS. A peak-detecting algorithm was used to 
detect calcium responses following each voltage stimulus, and the threshold for a positive 
response was set to 20% of an individual neuron’s maximum ∆F/F0 peak height298. This 
on-off binarization of sensory neuron Ca2+ signaling, when assessed by GCaMP 
fluorescence, has been previously reported by Hartung and Gold311. For each DRG, the 
percent of responding neurons at each voltage amplitude was calculated by normalizing 
the number of responding neurons at each amplitude by the highest number responding 







4.2.9 Statistical analysis 
All statistical analyses were performed in Prism 8 (GraphPad, San Diego, CA). A 
repeated measures two-way ANOVA with Bonferroni post-hoc was used to test for 
differences in percent responding cells at each voltage between trials in repeatability 
experiments. A constrained sigmoidal fit was performed on population response data to 
determine a half-maximal response voltage (EV50) and area under the curve (AUC) was 
calculated. A paired student t-test was used to compare EV50 and AUC values between 
trials in reproducibility experiments. To test for an effect of TTX dose on cellular 
responses, a repeated measures one-way ANOVA with Dunnett’s post-hoc was used to 
compare EV50 and AUC values at each TTX dose to the 0 µM untreated control. A 
repeated measures two-way ANOVA with Bonferroni post-hoc was used to test for 
differences in behavioral outcomes at each timepoint. To test for differences in EV50 and 
AUC values amongst ipsilateral and contralateral DRGs following peripheral nerve injury 
an unpaired student t-test was performed. To investigate the influence of cell size on EFS 
responsiveness following TTX treatment, neurons were sorted by soma diameter into 
three groups (diameter < 20 µm, 20 µm < diameter < 25 µm, diameter > 25 µm) and a 
repeated measures two-way ANOVA was used to compare EV50 values between 
conditions195. Relationships between 50% withdrawal threshold in hindpaw sensitivity 
trials collected prior to sacrifice and AUC were tested via linear regression followed by an 







4.3.1 EFS responses are reproducible 
In DRGs harvested from Advillin-GCaMP6s mice, we identified on average more 
than 200 individual GCaMP expressing soma within each imaging field (221±64). 
Following EFS, an increase in GCaMP fluorescence intensity was transiently observed 
(Fig. 4.4A), individual cellular responses at each voltage amplitude were well conserved 
between trials (Fig. 4.4B). Neurons were largely quiescent at EFS amplitudes below 20 
V, with only 2.4 and 22.3% of cells responding at EFS voltage amplitudes of 5 and 10 V 
on average, respectively (Fig. 4.4C). Within reproducibility validation experiments, there 
were no detectable differences in percent responsive cells at each voltage in sequential 
EFS trials (Voltage p<0.0001, Trial p=0.201, n=13 DRGs with n≥113 cells per DRG). 
Based on observed voltage-response behaviors, data were fit with a sigmoidal function 
on logarithmically transformed voltage amplitudes, and subsequent voltage-response 
data are presented as linear-log plots. Furthermore, there were no detectable differences 
between EV50 (p=0.923) or AUC (p=0.252) values between individual trials (Fig. 4.4D,E). 






Figure 4.4: EFS produces similar responses in serially stimulated intact DRG neurons. 
(A) Neurons within intact DRG tissues showed increased GCaMP6s fluorescence shortly following EFS  
(B) Representative traces of an individual neuron in sequential EFS trials, all detected responses are 
marked by a closed or open circle in the first and second trials, respectively. The dotted line represents 
the peak height cutoff, which is 20% of the maximum peak height. (C) In subsequent trials, DRG neurons 
responded similarly to voltage sweeps, and there were no differences in the percent of responding 
neurons at any voltage (Repeated measures two-way ANOVA; Voltage p<0.0001, Trial p=0.201, 
mean±SEM). No significant alterations were observed in EV50 (p=0.923) (D) or AUC (p=0.252) (E) 
values. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc to test for differences between 
trials at each voltage amplitude, paired student t-test to test for differences between trials in EV50 and 
AUC (n=13 DRG, with n ≥ 113 cells per tissue). Mean±SEM, sigmoidal fit ± 95% CI. 
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4.3.2 Small molecule sodium channel inhibition reduces EFS induced 
signaling 
 To test for an ability to use the described EFS imaging method as a drug screening 
platform, DRGs (n=5 with n≥138 cells per DRG) were treated with the voltage-gated 
sodium channel inhibitor, TTX. Following TTX treatment, DRG neurons showed a marked 
reduction in EFS evoked Ca2+ signaling (Fig. 4.5A,B). This reduced cellular 
responsiveness led to a rightward shift in the voltage-response curve with increasing 
concentrations of TTX (Fig. 4.5C). A dose-dependent increase in EV50 was observed with 
increasing TTX dose (p<0.0001, Fig. 4.5D). Significantly increased EV50 values were 
observed at 1 (p=0.0006) and 10 µM (p<0.0001) TTX doses compared to the untreated 
negative control. Prior to TTX treatment, the average EV50 within DRGs was 13.4 V, with 
TTX treatment these values increased to 51.5 and 60.6 V at 1 and 10 µM TTX doses, 
respectively. A corresponding dose-dependent reduction in AUC values were observed 
with increasing TTX dose (p<0.0001); significant reductions in AUC were observed with 
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1 (p=0.0003) and 10 µM (p<0.0001) TTX doses when compared to the untreated negative 
control (Fig. 4.5E). TTX-sensitive voltage-gated ion channels are expressed robustly on 
soma of differing size and sensory-modality; to investigate the effect of TTX inhibition 
across these neural sub-populations soma were stratified by cellular diameter. Soma size 




Figure 4.5: Tetrodotoxin inhibits EFS mediated Ca2+ signaling in intact DRG neurons. (A) Post 
EFS (100 V) GCaMP6s fluorescence dynamics were noticeably reduced with tetrodotoxin (TTX) 
treatment, and average ∆F/F (B) values across all cellular regions of interest (n=163 for displayed 
representative traces) within DRG tissues had reduced amplitude with TTX treatment. Data from one 
representative DRG tissue is shown. (C) TTX incubation led to a dose dependent decrease in EFS 
mediated cellular response (mean±SEM). (D) An increase in EV50 was observed at 1 (p=0.0006) and 
10 µM (p<0.0001) TTX doses while AUC (E) decreased at 1 (p=0.0003) and 10 µM (p<0.0001) TTX 
doses when compared to untreated controls. Repeated measures one-way ANOVA w/ Dunnett’s post-
hoc was used to test for differences between individual TTX doses and the untreated 0 µM control; 
**=p<0.01, ****=p<0.0001. Dotted line represents 0 µM control, (n=5 DRG, with n ≥ 138 cells per DRG). 
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4.3.3 Peripheral nerve injury resulted in unilateral hypoesthesia 
Surgically induced nerve injury resulted in clear alterations to animal behavior 
including impaired motor function upon ambulation in the injured hindlimb which began to 
improve 14 days following surgery. Following peripheral nerve injury, animals exhibited a 
decreased sensitivity to light touch in the ipsilateral hindpaw on days 7 (p<0.0001), 14 
(p<0.0001), 21 (p=0.0011), and 28 (p<0.0005) when compared the contralateral hindpaw 
(Fig 4.6A). Furthermore, an increased latency to withdrawal from a hot thermal stimulus 
was observed at the ipsilateral hindpaw on days 7 (p=0.0149), 14 (p<0.0066), 21 
(p<0.0001), and 28 (p=0.0022) when compared to the contralateral hindpaw (Fig 4.6B). 
  
 
Figure 4.6: Surgically induced peripheral nerve injury reduces mechanical and thermal 
sensitivity at the injured hindpaw. (A) Reduced mechanical sensitivity in the ipsilateral hindpaw was 
observed 7 (p<0.0001), 14(p<0.0001), 21(p=0.0011), and 28 (p<0.0005) days following nerve injury 
when compared to contralateral hindpaws. (B) Increased latency to withdrawal from a hot thermal 
stimulus (55°C) at the ipsilateral hindpaw was observed 7 (p=0.0149), 14(p=0.0066), 21(p<0.0001), and 
28 (p=0.0022) days post-injury when compared to the contralateral hindpaw. Repeated measures two-
way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. 
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4.3.4 EFS reveals increased voltage response threshold of ipsilateral 
DRGs following peripheral nerve injury 
 The excitatory behaviors of ipsilateral DRG neurons were altered following 
surgically induced peripheral nerve injury. A rightward shift in the voltage response curve 
was observed in ipsilateral DRGs (Fig. 4.7A). A corresponding increase to EV50 
(p=0.0106) and decrease in AUC (p=0.0224) was apparent in ipsilateral DRGs when 
compared to their level matched contralateral DRGs (Fig. 4.7B,C). Furthermore, reduced 




Figure 4.7: EFS reveals increased voltage response threshold in ipsilateral DRGs following 
peripheral nerve injury. (A) One month following nerve injury acutely isolated DRGs exhibited a 
rightward shift in their voltage response behavior. (B) Ipsilateral DRGs had an increased EV50 
(p=0.0106) and (C) decreased AUC (p=0.0224) values when compared to contralateral DRGs. (D) 
Decreased sensitivity at the hindpaw corresponded with reduced AUC values upon ex vivo assessment 





Here, we describe the development of a novel ex vivo imaging technique for the 
simultaneous visualization and functional assessment of hundreds of sensory neurons in 
intact DRG tissues. By utilizing genetic techniques to drive the robust expression of 
GCaMP6s in Advillin-expressing neurons, we showed an ability to reproducibly capture 
voltage-dependent EFS mediated signaling dynamics; furthermore, we showed an ability 
to measure pharmacologically induced alterations to functional signaling upon voltage 
mediated EFS. Finally, this method was shown to detect a change in ex vivo DRG 
responses consistent with pain-sensitivity related behavioral changes in a surgically 
induced nerve injury model. These results highlight the potential utility of the described 
method. 
While enzymatic digestion and mechanical dissociation of DRG neurons following 
axotomy remains the gold standard preparation for in vitro experiments of isolated 
sensory neurons, alterations to cellular phenotype have been documented in neurons 
when plated in monolayer culture. In addition to obvious artifact introduced by cellular 
dissociation, the spatial organization of individual soma and axons within the DRG are 
lost with cellular isolation315. Kim and colleagues have previously shown that with nerve 
injury, increased calcium signaling occurs in adjacent soma mediated in part through 
CX43-expressing glial cells, an observation that is lost in dissociated cultures due to 
disruption of neuron-glial cell interaction195. Furthermore, the effects of dissociation may 
change with time in culture: glial cells have been shown to progressively separate from 
sensory neuron soma over a one week culture period302. Extended culture periods often 
require the addition of exogenous factors, such as mitotic inhibitors or growth factors, to 
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prevent over-proliferation of satellite cells and improve viability in sensory neurons, 
respectively. Mitotic inhibitors have been shown to reduce antero- and retro-grade 
neuronal axonal transport in vitro and animal models have shown their systemic 
administration may result in chronic pain305,316. The inclusion of supplemented growth 
factors in vitro increases basal intracellular production and extracellular release of 
calcitonin gene-related peptide upon stimulation. In vivo studies have also highlighted the 
potential for nerve growth factor to benefit the survival of small-diameter neurons, 
whereas the pro-survival effects of neurotrophin-3 have been shown in larger-diameter 
proprioceptive neurons317–319. These factors may further contribute to a shift in cell 
population with time in prolonged sensory neuron monolayer culture.  
Prior work has shown EFS can be utilized for the simultaneous and unbiased 
activation of action potentials in large numbers of sensory neurons309,320–322. Fouillet and 
colleagues utilized EFS in the development of an in vitro drug screening platform and 
showed that with increasing doses of TTX, dissociated monolayer cultures of DRG 
sensory neurons exhibited reduced responses to voltage-mediated stimuli, similar to the 
results presented in this study309. Others have shown the importance of both high-voltage-
gated calcium channels and VGSCs in the generation of EFS mediated Ca2+ influx323. 
Similar work has utilized micro-electrode arrays for the in vitro assessment of various 
pharmacologic modulators of neuronal activity measuring Ca2+ mobilization in response 
to voltage stimuli324. We believe, however, the method shown in the current study 
provides important advantages over these prior techniques for its abilities to 
simultaneously assess firing rates in hundreds of cells while maintaining tissue integrity 
and single-cell firing resolution. Furthermore, the described method does not require 
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exogenous dye loading and instead relies on Cre-driven expression which reduces EFS 
experimental prep-times and ensures fluorescence cell-type-specificity and robust 
genetically encoded protein expression. This is in contrast to exogenous dye loading 
which relies on non-specific diffusion-based cellular uptake or micropipette injection197.   
Surgically induced peripheral nerve injury resulted in desensitization to mechanical 
and thermal stimuli at the injured hindpaw. These behavioral alterations following tight 
ligation were similar to those reported following either sciatic nerve crush or 
transection325–327. Following peripheral nerve injury in this model, we also observed 
alterations in EFS mediated DRG neuron excitability. Others have noted reduced 
transcriptional and protein level expression of voltage-gated sodium channels Nav1.1, 
Nav1.6, Nav1.7, Nav1.8, and Nav1.9 in DRGs following peripheral nerve injury which may 
partly explain our findings for increased EV50 in ipsilateral DRGs328–330. 
While the described method has some intrinsic benefits over standard dissociation 
based protocols, DRG isolation still requires axotomy, and as a result alterations to 
neuron excitability using this method are representative of somatic changes. While 
alterations within the soma are linked to changes at the site of peripheral sensory 
innervation, this method as described does not allow for the direct interrogation of fully 
intact sensory units. A further concern is that the electrical impedance of the isolated DRG 
may result in a heterogeneous electric field across the tissue. These differences, 
however, are expected to have little effect given the dimensions of individual cells in 
proportion to the DRG tissue. Additionally, observations in this study were consistent 
across neurons within DRG of varying size.  
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In conclusion, these data suggest an ability to use EFS in intact DRGs to 
simultaneously study the functional signaling dynamics in hundreds of neurons with 
single-cell resolution. Using the genetically encoded calcium indicator GCaMP6s together 
with standard spinning-disk confocal microscopy, we were able to assess alterations to 
EFS induced population responses of DRG neurons following pharmacologic modulation 
and injury. Taken together, these results suggest the described imaging approach 
possesses the sensitivity required for the functional assessment of DRG neuron 
excitability ex vivo. 
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Conclusions and Future Directions 
5.1 Conclusions 
This dissertation aimed to better understand how traumatic joint injury, and 
subsequent NF-κB activation influences the symptomatic progression of PTOA. In 
Chapter 2, data highlighted the transient alterations to whole joint NF-κB signaling shortly 
following non-invasive knee joint injury. Work also established the temporal presentation 
of various evoked and non-evoked pain-sensitivity related behaviors including the 
development of chronic allodynia as well as short term alterations to ambulation/gait. 
Severe joint degeneration was also observed four months following traumatic knee joint 
injury.  
Given the observed changes to whole joint NF-κB signaling and pain-sensitivity 
related behaviors following joint injury, we hypothesized early and local NF-κB inhibition 
would attenuate symptomatic and structural disease progression. Within Chapter 3, work 
described the synthesis and characterization of SF and PEG-PLGA microparticles for the 
sustained release of the NF-κB inhibitor, PHA-408. Both microparticle formulations 
effectively entrapped PHA-408 and exhibited sustained drug release for over two months 
in vitro. Drug released from microparticles was further shown to be bioactive and reduced 
inflammatory mediated signaling in an NF-κB luciferase reporter cell line. While intra-
articular delivery of free PHA-408 provided a modest acute chondroprotective benefit, its 
local delivery had limited influence on the development of pain-sensitivity related 
behaviors, and did not reduce the extent of degenerative changes to articular cartilage at 
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late timepoints following knee joint injury. Furthermore, intra-articular delivery of sustained 
release formulations did not overtly impact early imaging or behavioral outcomes. Drug 
clearance studies showed PHA-408 was rapidly cleared from the knee joint following local 
delivery, this may explain the drugs limited influence on the outcomes measured in this 
dissertation. 
Together, these data provide valuable insight into the symptomatic progression of 
PTOA in a non-invasive murine model. Specifically, this work serves to provide a baseline 
set of pain-sensitivity related behavioral changes that future studies may further 
interrogate. It also establishes the utility of this model for the study of symptomatic PTOA 
given its clear behavioral phenotype and clinically relevant mechanism of disease 
initiation. Finally, this work highlights the challenges of intra-articular small molecule 
delivery in the disease-modifying treatment of PTOA.  
Additional work in this dissertation sought to develop improved methods for the 
rapid and unbiased en bloc functional assessment of DRG neurons. Work in Chapter 4 
established an Advillin-GCaMP6s mouse line which was used to establish ex vivo 
methods to assess sensory neuron excitability to electric field stimulation within intact 
DRG tissues. The described high-throughput technique was shown to reproducibly 
measure Ca2+ activity following electric field induced action potential generation. Data 
further showed this method could be used to detect cellular signaling alterations in 
response to peripheral nerve injury and pharmacologic ion channel inhibition. This 
technique may help researchers improve an understanding of neural signaling while 
retaining tissue structural organization. More generally, this approach serves as a new 
tool for the rapid and large-scale ex vivo recording and assessment of neural activity. 
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5.2 Future Directions 
This dissertation provides additional understanding into the temporal progression 
of symptomatic disease in a non-invasive murine model of PTOA. Nevertheless, the 
mechanisms that contribute to both the acute and long-term development of pain-
sensitivity related behaviors remain elusive. We hypothesized that chronic activation of 
NF-κB within the injured joint would contribute to persistent pain-sensitivity related 
behaviors. This, however, was not supported by the data in this dissertation. To more 
closely probe how longitudinal NF-κB activity within joint tissues affects the development 
of pain-sensitivity behaviors, cell-type specific transgenic approaches that modulate or 
sense NF-κB activation within particular joint tissues may be of benefit67,331,332. 
Furthermore, studies targeted to investigate the symptomatic impacts of musculoskeletal 
injury should make use of non-evoked behavioral assessments that minimize animal 
handling and external stressors as these factors have been shown to influence 
outcomes122,333. 
While local delivery of PHA-408 provided no long-term benefit to joint health within 
this dissertation, it remains unclear as to whether alternative dosing strategies would 
provide a therapeutic benefit given the rapid onset and severity of degenerative changes 
observed in this model119. Additional studies are suggested to more thoroughly 
investigate the disease-modifying potential of PHA-408, and similar NF-κB inhibitors, in 
the context of PTOA. Such studies may benefit from using more slowly progressing PTOA 
models, or earlier endpoints in the described model, paired with more frequent drug 
dosing if their goal is to highlight drug efficacy77,106,142,164,274,334.  
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Although it is well established that NF-κB plays a prominent role in inflammation 
and associated pain-sensitivity, pharmacologic treatment strategies that target known 
upstream mediators of nociception (e.g. voltage-gated and mechanosensitive ion 
channels) may be of benefit in treating symptomatic PTOA14. Indeed, the use of ion 
channel agonists such as capsaicin and resiniferatoxin have shown benefit in reducing 
OA pain335,336. However, the pharmacologic modulation of other ion channels in 
symptomatic OA remains a promising and understudied avenue for the analgesic 
treatment of disease14,254,290,337,338. As an extension of the work in this dissertation, DRGs 
were isolated from mice 4 months following knee joint injury and immunostained 
(Appendix B, Supplementary Methods) for the voltage-gated sodium channels NaV1.8; 
preliminary results suggested a marked increase in the pain-related ion channel when 
compared to DRGs isolated from age matched uninjured controls (Appendix B, Fig. B.9). 
Thus, local treatments that directly antagonize these channels may provide favorable 
symptomatic relief and should be further explored in the context of this PTOA model337,339. 
Additional molecular and cellular profiling of the nervous system within this non-invasive 
model is also warranted to identify novel analgesic targets in PTOA. Future studies may 
utilize the novel ex vivo functional and structural (Appendix D, Fig. D.1-D.4) imaging 
methods developed in this dissertation to interrogate DRG neuron sensitivity or 
morphometric changes to knee joint structure following injury, respectively. If paired with 
retrograde/anterograde labeling techniques, the described methods may also be used to 
assess functional sensitivity and structural organization of DRG neurons known to 
specifically innervate distal joint structures340,341. Together these strategies may provide 
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for a more comprehensive understanding of how degenerative changes within the joint 
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Supplementary methods and results from Chapter 2 
Joint laxity testing 
Murine cadavers (male, 9-12 weeks of age, n=10) underwent cyclic compressive 
loading (as described in Section 2.2.1) of a randomly assigned knee joint to induce 
ligamentous injury. Hindlimbs were then dissected and scored by three blinded 
investigators for anterior-posterior laxity (0=naive, 1=increased anterior-posterior laxity). 
Summed scores for each joint were calculated and CTRL and INJ joint scores were 
compared via a Mann Whitney test. 
Correlation of longitudinal measures 
To test for relationships between early NF-κB-driven luminescence and 
longitudinally measured behavioral outcomes Pearson correlation coefficients were 
calculated. In vivo imaging and 50% withdrawal threshold data were log-transformed 
(base 10). All data were then normalized by each animals’ baseline values, represented 
as the difference from baseline, and the area under the curve was calculated in early (0 
to 7/8 d) and late (15 to 113 d) study windows. Data were then z-scored and Pearson 
correlation coefficients were calculated. Early and late windows were chosen based on 
observed NF-κB luminescence temporal dynamics.  
To test for relationships between OARSI scores and early NF-κB-driven 
luminescence as well as chronic behavioral changes, summed OARSI scores 
(LFC+LTP+MFC+MTP) were calculated. Area under the curve was calculated within a 
chronic (57 to 113 d) study window for baseline corrected behavioral measures. Data 
[128] 
 
were then z-scored and Pearson correlation coefficients were calculated. The chronic 
window used in this analysis was based on previous reports of cartilage degeneration 
within this model which have shown OARSI scores remain similar between 56 and 112 d 







Figure A.1: Within groups thermal latencies are bilaterally similar. (A and B) Latency to withdrawal 
from a hot (50°C) stimulus at the hindpaw in CTRL (time p<0.0001, limb p=0.123, interaction p=0.989) 
and INJ (time p=0.0002, limb p=0.328, interaction p=0.228) groups. (C and D) Latency to withdrawal 
from a cold (0°C) stimulus at the hindpaw in CTRL (time p<0.0011, limb p=0.707, interaction p=0.889) 
and INJ (time p=0.0220, limb p=0.199, interaction p=0.493) groups. Mean±SD, repeated measures 
(both factors) two-way ANOIVA. 
 
Figure A.2: Measures of ambulation within short recording periods are highly variable. (A) 
Individual distance traveled traces within a 30 min recording period highlight the highly variable 
ambulatory behaviors within CTRL mice. Missing datapoint within INJ group due to animal death. (B) 
Animal distance traveled within 5 minute time bins decreased over the duration of the 30 minute open 






Figure A.3: Relationships between early NF-κB and behavior. Early NF-κB luminescent scores were 
correlated with early and late allodynia withdrawal-scores (A) and late hyperalgesia withdrawal-scores 
(B). No significant correlations between early NF-κB luminescent-scores and weight bearing- (C), hot- 
(D), or cold-scores (E) were observed within early or late time windows. Pearson correlation coefficient, 
r2, and p-values are indicated. Two datapoints in thermal correlations are missing due to instrumentation 
malfunction on day 0, thus baseline corrected values could not be calculated. 
 
 
Figure A.4: Relationships between NF-κB, behavior, and histological outcomes. (A) Early NF-κB 
luminescent scores were correlated with terminal OARSI-scores. (B) OARSI-scores were correlated 
with chronic allodynia withdrawal-scores. (C) No significant correlations between terminal OARSI-
scores and chronic hyperalgesia- (C), weight bearing- (D), hot- (E), or cold-scores (F) were observed. 
Pearson correlation coefficient, r2, and p-values are indicated. Two datapoints in thermal correlations 






Supplementary methods and results from Chapter 3 
Dorsal root ganglia immunostaining 
At the terminal timepoint, 113 days following knee joint loading, animals were 
sacrificed by exsanguination and subsequently transcardially perfused with 4% PFA. 
Ipsilateral lumbar level 4 dorsal root ganglia (DRG) were then isolated, post-fixed (4 h, 
4°C), cryoprotected in 30% sucrose (overnight, 4°C), flash-frozen in optimal cutting 
temperature compound, and cryosectioned (n=4 CTRL, n=3 INJ, n=3 INJ/Tx) at 7 µm. 
Slides with the largest number of cell bodies were selected from each DRG and 
underwent antigen retrieval (citrate buffer, 30 min, 90°C, pH 6.0), and permeabilization 
(0.2% Triton, 20 min). Samples were then blocked in 5% goat serum + 0.2% Triton (30 
min) and subsequently stained in blocking buffer with primary antibody (rabbit anti-
NaV1.8, 1:100, Alomone Labs, ASC-016, overnight, 4°C) or isotype (rabbit IgG) control. 
Samples were then washed (3X, PBS+ 0.1% Tween20), stained with secondary antibody 
(goat anti-rabbit Alexa 488, 1:300, Invitrogen, 1 h) in blocking buffer, washed (3X) again, 
and nuclei were counterstained with DRAQ5 (1:1000, 10 min). Samples were then 
coverslipped and imaged upon a Lecia DM6 confocal microscope at 20X (ACS APO 
20x/0.60 IMM). Z-stacks (5 steps, 2.2 µm step-size) were taken of all DRG and maximum 
intensity projections were used for subsequent analysis. Image analysis was performed 
in ImageJ, all intact cell soma within each imaging field were manually traced (n=676 
CTRL, n=367 INJ, n=311 INJ/Tx) and mean fluorescent intensity (MFI) and area were 
[132] 
 
calculated. MFI values were then compared between groups using a one-way ANOVA 






Figure B.1: Repeated acute intra-articular administration of PHA-408 reduces allodynia in the 
MIA injection model of arthritis. Following intra-articular injection of mono-iodoacetate (0.1 mg, MIA) 
repeated intra-articular delivery of PHA-408 (0.1 µg, 0 and 48 h, Tx) reduced ipsilateral hindpaw 
allodynia when compared to mice receiving a Veh injection, no sensitivity alterations were observed 
between groups in contralateral (C) hindpaws. Mean±SD, repeated measures two-way ANOVA w/ 
Bonferroni’s post-hoc; *=p<0.05, ***=p<0.001. 
 
 
Figure B.2: Reporter cell responses are stimulus- and time-dependent (A) SW982 NF-κB luciferase 
reporter cell line was responsive to IL-1β and lipopolysaccharide (LPS), one-way ANOVA w/ Dunnett’s 
post-hoc. (B) NF-κB-driven bioluminescent signal is increased if PHA-408 treatment is delayed following 
stimulation with IL-1β (1 ng/mL). Data is normalized to IL-1β-only treated control (dotted line=mean of 













Figure B.3: PHA-408 suspension size. (A) PHA-408 drug particles were readily visible via epi-
fluorescent microscopy at the injected concentration (0.6 mg/mL). (B) Particle diameter was 2.09±0.53 
µm. Scale bar = 20 µm. 
 
Figure B.4: LC-MS PHA-408 tissue standard curves. Standard curves are shown for each tissue 






Figure B.6: NF-κB activation due to intra-articular injection of PHA-408 is minimal, but not 
reduced when compared to vehicle control. Naive mice received one intra-articular injection (t=0) of 
either PHA-408 (3ug/5uL, n=5) or vehicle control (saline+0.1% DMSO, n=4). Intra-articular injection of 
PHA-408 or vehicle led to an increase in joint localized NF-κB-driven luminescence in injected knees 
when compared to contralateral (C) knees, however, local delivery of PHA-408 did not lead to a 
reduction in NF-κB-driven luminescence when compared to vehicle control. Mean±SD, repeated 
measures two-way ANOVA w/ Bonferroni’s post-hoc to test for differences between all treatment groups; 
*=p<0.05. Dotted and solid lines represent average ROI radiance values for INJ and INJ/Tx ipsilateral 
knee joints 3 days post-injury, respectively. 
 
Fig. B.5: A sustained release microparticle did not improve PHA-408 concentrations within the 
joint. Following one-time local delivery of PHA-408 loaded SF microparticles (50 µg PHA-408,120 MB 
formulation, t=0 h), drug was not detected within (A) injected knee joint tissues 24, 48, 72, or 96 h post-
injection. Peak concentration in (B) serum and (C) urine were detected 48 h post microparticle injection 
(n=2-3 per timepoint). Concentrations from suspension based PHA-408 (3 µg, t=0 and 48 h) intra-





Figure B.8: Ex vivo PHA-408 treatment reduces NF-κB signaling, nitric oxide release, and sGAG 
loss following an inflammatory stimulus in musculoskeletal organ cultures. (A) Experimental 
timeline. (B) NF-κB luminescence over time and (C) area under curve (AUC) from murine functional 
spinal unit organ cultures. (D) Nitric oxide (NO) and (E) sGAG released into media. (F) Tissue 
associated sGAG. Mean±SD, one- or two-way ANOVA w/ Dunnett’s post-hoc, *=p<0.05 vs vehicle 
control. 
 
Figure B.7: Small molecule NF-κB inhibition influences cell viability in a dose dependent manner. 
(A) SW982 cells had reduced viability after 24 hr treatment with either PHA-408 or SC-514, a similar 





Figure B.9: Alterations to NaV1.8 protein expression in L4 ipsilateral dorsal root ganglia neurons 
with injury. At the terminal timepoint, ipsilateral dorsal root ganglia (DRG) were isolated from the L4 
spinal level and stained for the voltage gated sodium channel NaV1.8. (A) Representative DRG from 
CTRL, INJ, and INJ/Tx groups show increased NaV1.8 staining intensity (B) in INJ and INJ/Tx DRG, 
however, INJ/Tx DRG had reduced staining intensity when compared to their untreated INJ 
counterparts. (C) NaV1.8 expression was highest in smaller DRG neurons. One-way ANOVA w/ Tukey’s 






Figure B.10: Ipsilateral to contralateral comparisons. Given the study design, ipsilateral to 
contralateral=C comparisons were made within each timepoint. (A) NF-κB-driven luminescence, (B) 
50% withdrawal threshold, (C) escape threshold, and latency to a (D) hot or (E) cold stimulus. Repeated 




Supplementary results from Chapter 4 
  
  
Figure C.1: Soma size does not influence neural responsiveness to EFS with TTX inhibition. (A) 
Responses in neurons of varying soma size were similar across TTX concentrations. Percent response 
values in each size group represent a portion of all responding neurons (mean±SEM). (B) No size-
based differences were observed in EV50 at any individual TTX concentration (TTX p=0.007, Size 




Optically clearing musculoskeletal tissues: methods 
development and application 
Introduction  
The gold standard approach for assessing degeneration in musculoskeletal 
tissues has long been histology227. Following a study endpoint, tissues designated for 
histological evaluation must be processed following a protocol that coincides with their 
ultimate embedding medium. This usually requires fixation, followed by a multiweek 
decalcification process and subsequent dehydration before embedding342. Then samples 
must undergo multiple resource intensive tasks including: sectioning, staining, imaging, 
and scoring343. This method has been invaluable in understanding how anatomy changes 
with disease; however, biology does not exist within the confines of a several micron thick 
section. As such, recent approaches have aimed to improve our three-dimensional 
understanding of biology by offering new tissue processing methods that support optical 
light transmission through thick tissues (“clearing”)344. By pairing old and new tissue 
clearing techniques with multi-photon or light-sheet microscopy many groups have been 
able to image intact samples and uncover intricacies of three-dimensional spatial biology 
that were overlooked or unresolvable in micron thick sections344–348. The majority of 
clearing techniques, however, have not been developed to address the unique challenges 
of musculoskeletal tissues349–353. Joints have a variety of tissue types with diverse 
physical properties in close proximity which pose as hurdles to clearing and imaging intact 
specimens354. However, by using a combination of clearing techniques paired with 
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fluorescent small molecules it may be possible to uncover morphometric changes to the 
joint following injury with an improved three-dimensional context. The work described in 
this appendix establishes clearing methods that have been optimized for imaging through 
musculoskeletal tissues. These methods are applied in a non-invasive murine model of 
PTOA to illustrate the early changes to joint morphology following joint injury.  
Methods 
Optical clearing method screening 
Several aqueous and non-aqueous tissue clearing methods were first screened in 
porcine cartilage plugs (Fig. D.1). Plugs (4 mm diameter) were biopsied from load-bearing 
 
Figure D.1: Clearing method development. (A) Graphical schematic of tissue clearing pipelines. (B) 
Representative images of tissues in respective clearing solutions (grid = 1 mm). (C and D) 
Representative SHG image stacks and MFI of signal throughout collected cartilage plug z-stacks. 
Mean±SEM, n=3 plugs/group. 
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regions of the tibial plateau. Transverse sections of the patellar tendon were also 
collected. Following isolation, tissues were fixed in 4% PFA (4 h, 4°C) and washed in PBS 
before clearing. All following steps were performed in solution volumes of roughly ten-
times that of the sample of interest, 15 or 50 mL polypropylene screw-top FalconTM tubes 
are typically preferred. Aqueous. TDE: Samples cleared in 2,2’-thiodiethanol (TDE, 
Sigma-Aldrich, St. Louis, MO) underwent sequential immersion in increasing 
concentrations of TDE in PBS (10%, 25%, 50%, 70%, 80%, and 100% vol/vol). The final 
concentration of TDE can be varied to tune its refractive index (RI) for imaging depending 
on sample RI355. Similar RI tunability can be attained with SeeDB, an aqueous fructose-
based clearing protocol356. Non-aqueous. Following dehydration in graded 
tetrahydrofuran (THF, pH 9.0, 4°C, Sigma-Aldrich) and dichloromethane (DCM, 25°C, 
Sigma-Aldrich), samples were immersed in their respective clearing solution. MS: 
Samples were immersed in methyl-salicylate (MS, Sigma-Aldrich) until clear, and then 
mounted in MS354. BABB: Samples were placed in benzyl alcohol-benzyl benzoate 
(BABB; 1:1 vol/vol, Sigma-Aldrich) until the samples were clear to the naked eye, followed 
by mounting in fresh BABB, the refractive index of BABB can be tuned by varying the 
BA:BB ratio357–360. DBE: Following dehydration samples were immersed in dibenzyl ether 
(DBE, Sigma-Aldrich) until clear and were then mounted in fresh DBE361. Special care 
should be taken when using these non-aqueous agents; polystyrene products should be 
avoided.  
Non-aqueous clearing methods appeared to more consistently reduce tissue 
opacity in cartilage and tendon; thus, they were used in further optimization for the en 
bloc imaging of murine knee joints. It has been previously reported that decalcification 
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and dehemification of musculoskeletal tissues may serve to reduce RI mismatch induced 
photon scattering and absorption, resepecitively351,362. Therefore, we investigated how 
these tissue constituents impacted an ability to resolve propidium iodide stained 
chondrocytes deep within intact knee joints. Mice (12-20 weeks of age, FVB.Cg-Tg(HIV-
EGFP,luc)8Tsb/J, Jackson Laboratory, Bar Harbor, ME) were euthanized via 
exsanguination and transcardially perfused with 4% PFA. Intact knee joints were 
harvested and post-fixed overnight (4% PFA, 4°C). Tissue surrounding the joint capsule 
was carefully trimmed and samples were then processed as outlined in Figure D.2A. A 
subset of knee joints were decalcified with 10% ethylenediaminetetraacetic acid (EDTA, 
pH 8.0, 37°C, 2 days, Sigma-Aldrich). Cell nuclei were stained with propidium iodide (PI, 
10 µg/mL, 25°C, 1 day, Sigma-Aldrich)352,363. An additional group of knee joints were 
treated to remove heme (“dehemed”) in 25% N,N,N′,N′-Tetrakis(2-
Hydroxypropyl)ethylenediamine (Quadrol + 1% Triton X-100, 37°C, 1 d, Sigma-Aldrich). 
Samples were then dehydrated in graded THFs and immersed in DBE as previously 
described. 
To illustrate the utility of this imaging technique, a non-invasive model of PTOA 
was used. Right knees of mice (12-16 weeks of age, FVB.Cg-Tg(HIV-EGFP,luc)8Tsb/J) 
underwent 60 cycles of either 6 or 12 N compressive loading29. Mice were then sacrificed 
either 7 or 14 days following injury. A subset of mice undergoing 12 N loading were 
sacrificed 28 days following injury. Following exsanguination (under isoflurane 
anesthesia, IACUC# 19-1032) mice received a transcardial perfusion of Lectin-DyLight 
649 (0.1 mg/ 100 µL, 1230/655-710 nm ex/em, Vector Labs, Burlingame, CA) to label 
vascular surfaces at the time of sacrifice364–366. 
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Visible light stereomicroscopy 
Following clearing, tissues were immersed in their final clearing agents within a 
glass petri dish and imaged via a visible light stereomicroscope (MZ125, Leica 
Microsystems, Buffalo Grove, IL) to qualitatively assess clearing efficacy (grid = 1.0 mm). 
Multiphoton microscopy 
Cleared cartilage plugs were secured in a custom-made imaging chamber with 
two-part epoxy and immersed in their respective clearing solution. Full-thickness second 
harmonic generation (SHG, 880/420-460nm ex/em) images were acquired from the 
superficial articular surface upon an upright multi-photon microscope (SP8 DIVE, Leica 
Microsystems). All imaging parameters were kept constant between groups.  
Cleared murine joints were imaged within the sagittal plane, intact joints were 
mounted with the medial side of the joint facing upwards towards the imaging objective. 
Serial planar images were collected from the medial collateral ligament (MCL) to a 
subsequent depth of 1 mm. All imaging parameters were kept constant between groups 
for clearing optimization and fluorescent PI (1045/630-660 nm, ex/em) and SHG 
(1045/510-530 nm, ex/em) signals were simultaneously collected. Scanning parameters 
in other images were chosen to balance image quality, scanning time, and file size. 
Multiphoton imaging was performed using a long working distance multi-immersion 
objective (FLUOTAR L 16x IMM CORR VISIR, NA=0.6, WD = 2.5 mm, Leica 
Microsystems). 
Image processing and analysis 
To aid in clearing protocol screening, quantitative analyses were performed on 
acquired images. The mean fluorescent intensity (MFI) at each imaging plane was 
[145] 
 
calculated within a region of interest (ROI). The selected ROI was defined to include 
articular surfaces of the femur and tibia within PI image stacks and the entire imaging 
field within SHG image stacks. Degenerative changes to synovium and articular cartilage 
were assessed to illustrate the potential utility of the described imaging techniques. Within 
planar images of the medial anterior synovium, a synovial ROI was defined (200 x 50 
µm)119. Cell nuclei within the ROI were manually counted to determine a nuclear number 
per unit area and thickness of the intimal synovial layer was manually measured at five 
locations within each ROI using ImageJ. Fluorescent images were also graded using a 
standard synovitis scoring system by two blinded investigators119,367. 
To assess focal alteration to cartilage, chondrocyte nuclei within a manually 
defined volume of interest (VOI) were segmented using an automated ImageJ code. VOIs 
were defined to include all tissues within 30 µm of the medial femoral condyle superficial 
surface. Following VOI segmentation images were cropped to reduce computational time. 
A three-dimensional Gaussian kernel was applied (2 x 2 x 4 voxels) followed by a rolling 
ball filter (20 voxel diameter) to minimize the impact of spatially varying background signal 
on binarization. Images were then binarized and a three-dimensional watershed and 
morphological opening (1 voxel structuring element) were used to help reduce 
overconnected binarized nuclei. Centroid positions for all nuclear objects could then be 
identified. A custom MATLAB script was used to calculate Euclidian centroid-centroid 
distances between all nuclear objects and these data were used to determine the three 
nearest neighbors of all nuclei. From these data, and observations of planar images, it 
was apparent 12 N injury led to a well-conserved focal lesion within the anterior region of 
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the medial femoral condyle which was more closely integrated within a smaller VOI (300 
x 30 x 100 µm). Nuclei per unit volume were calculated within this VOI. 
Results and Discussion 
Optical clearing increased qualitative sample transparency (Fig. D.1B), less 
opaque samples had increased depth-resolved SHG signal (Fig. D.1C,D). Decalcification 
of intact murine joints improved sample transparency, particularly in calcified joint 
structures, while heme removal had a minimal qualitative impact on sample clarity (Fig. 
D.2C). Decalcified samples had a trend of increased PI (Fig. D.2E) and SHG (Fig. D.2F) 
 
Figure D.2: Clearing optimization within murine joints. (A) Graphical schematic of generalized knee 
clearing pipeline. (B) Steps and time to completion for each protocol following tissue fixation. (C) 
Representative brightfield images of murine joints cleared using each protocol (grid = 1 mm). (D) Field 
of view (FOV) used in subsequent sagittal plane image stacks. (E and F) Representative depth resolved 
images and (G and H) quantification of propidium iodide (PI) and second harmonic generation (SHG) 
images, respectively. Signal intensity within the defined region of interest (ROI) are plotted as well as a 
qualitative z-depth limits of cellular and collagen morphology resolution. Mean, n=2-3 knees/group. 
PM=posterior meniscus, AM=anterior meniscus, MFC=medial femoral condyle, MTP=medial tibial 




signal at deeper imaging depths within the imaging ROI. The qualitative limit of cellular 
resolution within non-decalcified samples was roughly 500 µm from the MCL, in 
decalcified samples individual PI stained nuclei could be seen at imaging depths of nearly 
800 µm (Fig D.2G), similarly, fibrillar collagen structures could be seen at depths of over 
1000 µm from the medial collateral ligament in decalcified samples (Fig D.2H). 
Furthermore, homogeneity of PI and SHG signal intensity across the imaging field was 
improved in decalcified samples. 
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Following knee joint injury (Fig. D.3A), joints tended to have increased synovial 
thickness and planar cell density within the intimal layer of the anterior synovium (Fig. 
D.3B,C). Synovitis scores were similar to those previously reported within this non-
invasive loading model at early timepoints119. A modest focal reduction in three-
dimensional chondrocyte density was observed within the anterior region of the MFC (300 
x 30 x 100 µm VOI) of 12 N loaded knee joints (Fig. D.3D-F).  
 
Figure D.3: En bloc imaging enables structural interrogation of joint tissues through optical 
sectioning. (A) Right knees underwent 6 or 12 N cyclical loading and mice were sacrificed within 14 
days of knee joint injury and were subsequently cleared using a decalcification-based protocol. (B and 
C) Anterior synovium of injured knee joints trended towards having increased thickness, cell nuclei per 
unit area, and higher histopathological scores. (D) Representative nuclear centroid maps of the medial 
femoral condyle display position and average distance to each nuclear objects’ three nearest neighbors, 
the outlined region in the 12 N image highlights a focal reduction in cellularity. (E and F) Nuclear object 
detection within a 30x300x100 µm volume of interest in the anterior region of the medial femoral condyle 





Morphological alterations to synovial vascular structures were observed 4 weeks 
following knee joint injury (Fig. D.4A,B). Additional early changes to cellularity were 
observed in other joint structures (e.g. posterior medial meniscus) following 12 N injury 
(Fig. D.4C). The described methods were also compatible with other tools (Fig. D.4D,E) 
frequently used within musculoskeletal research (e.g. fluorescent reporters, dynamic 
bone labeling). 
These data suggest optical clearing may serve as a first-pass method to assess 
changes in musculoskeletal tissue structures in novel animal models where the spatial 
position of a phenotype may be unknown. This technique is of particular value in focal 
diseases such as PTOA where different sectioning planes may show vastly different 
degrees of degneration35,36. Others have emphasized this limitation of gold standard 
 
Figure D.4. Additional applications of musculoskeletal tissue clearing (A-C) Alterations in the 
morphology of lectin labeled vascular structures were observed in anterior synovium 28 days following 
12 N knee joint injury. Additional focal changes to knee joint cellularity were observed in knee joint 
structures such as the medial meniscus within 7 days of 12 N injury. (D-E) Tissue clearing protocols 
were also shown to be compatible with transgenic fluorescent reporters (murine rib and surrounding 




histopathological assessments in the context of PTOA. For example, Glasson and 
colleagues highlight the high degree of degenerative changes following ACL transection 
in the posterior aspect of the tibial plateau107. These erosive changes are outside of the 
typical mid-contact region which is typically assessed histologically within the coronal 
plane227. Thus, sections scored from the mid-contact region within ACL transection knees 
might not accurately represent the full extent of joint degeneration. Non-destructive 
imaging techniques, such as those described here, may help to overcome these 
limitations. Following identification of an ideal sectioning plane or region of interest, 
standard histological techniques can still be used to assess morphometric, phenotypic, 
and cellular changes via more well-established measures.  
Despite the described benefits of clearing and en bloc imaging, the technique is 
not without limitations. Clearing methods have mostly been developed to improve en bloc 
imaging in soft tissues with relatively homogenous tissue constituents349. The 
heterogeneity of tissues in the joint presents several hurdles for which the developed 
tissue clearing methods are unable to fully overcome. For example, the RI mismatch 
between bone and DBE was apparent in non-decalcified samples where bone appeared 
to be more opaque than surrounding tissues. Decalcification helps to reduce the RI of 
bone thereby homogenizing the RIs within the joint space354,368. Ultimately this reduces 
the number of scattering events for incident and emitted photons and improves axial 
resolution. However, there remains structural and RI inhomogeneities throughout these 
cleared tissues which result in uneven illumination due to differing light-path interactions. 
This makes robust quantification of acquired images difficult. For this reason, intensity-
based quantification, particularly over large fields-of-view, has limited accuracy352. 
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Feedforward intelligent imaging controls may help to improve signal-to-noise by actively 
modulating laser intensity and detector gain depending on previously collected imaging 
data. Recent advances in deep-learning neural network based segmentation have also 
sought to address these image analysis based shortcomings and have led to more 
accurate quantification of such volumetric imaging datasets369. Nevertheless, en bloc 
imaging serves as a valuable companion method to investigators within the 
musculoskeletal field for assessing the three-dimensional microscale changes to intact 
tissues and organs without the immediate need for laborious histological techniques.  
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